

Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER **Bids and Awards Committee**

Quezon Avenue, Quezon City 1100 website: www.pcmc.gov.ph email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION I

Invitation to Bid

Supply and Delivery of Various Supplies for CY 2023



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City 1100
website: www.pcmc.gov.ph email: officeofthedirector@pcmc.gov.ph
Trunk Line: 8588-9900 to 20 Direct Line: 8924-6601

INVITATION TO BID

The Philippine Children's Medical Center (PCMC) through the COB CY 2023 intends to apply the sum of One Hundred Twenty-Three Million One Hundred Twelve Thousand Eight Hundred Twenty-Two Pesos and 51/100 (Php 123,112,822.51) being the Approved Budget for the Contract (ABC) to payments under the following Invitation to Bid. Bids received in excess of the ABC shall be automatically rejected at bid opening.

| IB No. | ITEM DESCRIPTION | ABC | COST OF COMPLETE SET OF BIDDING DOCUMENTS |
|----------|---|----------------|---|
| | SUPPLY AND DELIVERY OF: | | |
| 2023-089 | Various Pharmaceutical Supplies CY 2023 | 112,508,915.79 | 50,000.00 |
| 2023-090 | Various Direct Medical Supplies CY 2023 | | |
| | A. Nephrology and Hemodialysis Supplies | 2,776,480.00 | 5,000.00 |
| | B. Pediatric Cardiology Supplies | 4,236,413.72 | 5,000.00 |
| | C. Pediatric Surgery Supplies | 2,277,889.56 | 5,000.00 |
| | D. Perinatology Supplies | 1,313,123.44 | 5,000.00 |

- 2. The Philippine Children's Medical Center (PCMC) now invites bids for the above-mentioned project. Delivery of the Goods is required within Seven (7) working days from receipt of Purchase Order/Delivery Order. Bidders should have completed, within the past two (2) years from the date of submission and receipt of bids, a contract similar to the Project. The description of an eligible bidder is contained in the Bidding Documents, particularly, in Section II. Instructions to Bidders.
- 3. Bidding will be conducted through open competitive bidding procedures using a nondiscretionary "pass/fail" criterion as specified in the 2016 revised Implementing Rules and Regulations (IRR) of Republic Act (RA) 9184, otherwise known as the "Government Procurement Reform Act".
 - a. Bidding is restricted to Filipino citizens/sole proprietorships, partnerships, or organizations with at least sixty percent (60%) interest or outstanding capital stock belonging to citizens of the Philippines, and to citizens or organizations of a country the laws or regulations of which grant similar rights or privileges to Filipino citizens, pursuant to RA No. 5183.
- 4. Prospective Bidders may obtain further information from PCMC and inspect the Bidding Documents at the address given below during office hours.

PhilHealth Accredited



Section I. Invitation to Bid

- 5. A complete set of Bidding Documents may be acquired by interested Bidders starting **July 11, 2023**, upon payment of the applicable fee stated above. It may also be downloaded free of charge from the website of the Philippine Government Electronic Procurement System (PhilGEPS) and the website of PCMC, provided that Bidders shall pay the applicable fee for the Bidding Documents not later than the submission of their bids.
- 6. The Philippine Children's Medical Center will hold a Pre-Bid Conference on July 19, 2023 at 10:00 A.M through video conferencing via Zoom (Meeting ID: 980 9175 9916 Passcode: IB20238990) which shall be open to prospective bidders.
- Bids must be duly received through manual submission on or before July 31, 2023, 1:30
 P.M., Guard-on-Duty, 3rd Floor, Procurement Division Area, PCMC Main Building. Late bids shall not be accepted.
- 8. All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in ITB Clause 14.
- 9. Bid opening shall be on **July 31, 2023, at 2:00 P.M.** Multi-Purpose Hall C, PCMC Main Building. Bids will be opened in the presence of the Bidder's representatives who choose to attend the afore-mentioned venue. In compliance to social distancing and to support the government's effort to mitigate, if not contain transmission of COVID-19, we will **strictly allow only one authorized representative** per bidder company to enter the venue during the opening of bids. Provided further, said authorized representative shall follow PCMC's safety protocol by wearing a face mask while inside PCMC Premises.
- 10. The **Philippine Children's Medical Center (PCMC)** reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Sections 35.6 and 41 of the 2016 revised IRR of RA No. 9184, without thereby incurring any liability to the affected bidder or bidders.
- 11. For further information, please refer to:

Procurement Division
3rd Floor, Procurement Division Area
PCMC Main Building
Quezon Avenue, cor. Agham Road Quezon City
Trunk line: 8588-9900 Loc 361 / 355

Fax Number: 924-0870 Email: pcmcbac@gmail.com

12. You may visit the following websites:

For downloading of Bidding Document: www.pcmc.gov.ph www.philgeps.gov.ph

July 11, 2023

FRANCIS S. DELA CUESTA, RN MAN Chairman, Bids & Awards Committee

IB-2023-089 to 90 Page 2 of 2

Section I. Invitation to Bid

Page 3 of 3



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Bids and Awards Committee

Quezon Avenue, Quezon City 1100

website: www.pcmc.gov.ph email: bac@pcmc.gov.ph
Trunkline: 588-9900 local 361/355 Telefax No.: 924-0870

SECTION II

Instructions to Bidders

Supply and Delivery of Various Supplies for CY 2023

1. Scope of Bid

The **Philippine Children's Medical Center (PCMC)** wishes to receive Bids for the following Project:

The above Procurement Projects, the details of which are described in Section VII (Technical Specifications).

2. Funding Information

- 2.1. The GOP through the source of funding as indicated below for CY 2023 in the amount of One Hundred Twenty-Three Million One Hundred Twelve Thousand Eight Hundred Twenty-Two Pesos and 51/100 (Php 123,112,822.51).
- 2.2. The source of funding is:
 - a. GOCC and GFIs, the Corporate Operating Budget

3. Bidding Requirements

The Bidding for the Project shall be governed by all the provisions of RA No. 9184 and its 2016 revised IRR, including its Generic Procurement Manuals and associated policies, rules and regulations as the primary source thereof, while the herein clauses shall serve as the secondary source thereof.

Any amendments made to the IRR and other GPPB issuances shall be applicable only to the ongoing posting, advertisement, or **IB** by the BAC through the issuance of a supplemental or bid bulletin.

The Bidder, by the act of submitting its Bid, shall be deemed to have verified and accepted the general requirements of this Project, including other factors that may affect the cost, duration and execution or implementation of the contract, project, or work and examine all instructions, forms, terms, and project requirements in the Bidding Documents.

4. Corrupt, Fraudulent, Collusive, and Coercive Practices

The Procuring Entity, as well as the Bidders and Suppliers, shall observe the highest standard of ethics during the procurement and execution of the contract. They or through an agent shall not engage in corrupt, fraudulent, collusive, coercive, and obstructive practices defined under Annex "I" of the 2016 revised IRR of RA No. 9184 or other integrity violations in competing for the Project.

5. Eligible Bidders

5.1. Only Bids of Bidders found to be legally, technically, and financially capable will be evaluated.

5.2.

a. Foreign ownership exceeding those allowed under the rules may participate pursuant to:

- i. When a Treaty or International or Executive Agreement as provided in Section 4 of the RA No. 9184 and its 2016 revised IRR allow foreign bidders to participate;
- ii. Citizens, corporations, or associations of a country, included in the list issued by the GPPB, the laws or regulations of which grant reciprocal rights or privileges to citizens, corporations, or associations of the Philippines;
- iii. When the Goods sought to be procured are not available from local suppliers; or
- iv. When there is a need to prevent situations that defeat competition or restrain trade.
- 5.3. Pursuant to Section 23.4.1.3 of the 2016 revised IRR of RA No.9184, the Bidder shall have an SLCC that is at least one (1) contract similar to the Project the value of which, adjusted to current prices using the PSA's CPI, must be at least equivalent to:
 - a. For the procurement of Expendable Supplies: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC of the items joined.
 - b. For procurement where the Procuring Entity has determined, after the conduct of market research, that imposition of either (a) or (b) will likely result to failure of bidding or monopoly that will defeat the purpose of public bidding: the Bidder should comply with the following requirements: [Select either failure or monopoly of bidding based on market research conducted]
 - i. Completed at least two (2) similar contracts, the aggregate amount of which should be equivalent to at least *fifty percent* (50%) in the case of non-expendable supplies and services or twenty-five percent (25%) in the case of expendable supplies of the ABC for this Project; and
 - ii. The largest of these similar contracts must be equivalent to at least half of the percentage of the ABC as required above.
- 5.4. The Bidders shall comply with the eligibility criteria under Section 23.4.1 of the 2016 IRR of RA No. 9184.

6. Origin of Goods

There is no restriction on the origin of goods other than those prohibited by a decision of the UN Security Council taken under Chapter VII of the Charter of the UN, subject to Domestic Preference requirements under ITB Clause 18.

7. Subcontracts

7.1. The Bidder may subcontract portions of the Project to the extent allowed by the Procuring Entity as stated herein, but in no case more than twenty percent (20%) of the Project.

The Procuring Entity has prescribed that:

a. Subcontracting is not allowed.

IB-2023-089 to 090 : Various Supplies CY 2023

8. Pre-Bid Conference

The Philippine Children's Medical Center will hold a Pre-Bid Conference on July 19, 2023 at 10:00 A.M through video conferencing via zoom (Meeting ID: 980 9175 9916 Passcode: IB20238990) which shall be open to prospective bidders, as indicated in paragraph 6 of the IB.

9. Clarification and Amendment of Bidding Documents

Prospective bidders may request for clarification on and/or interpretation of any part of the Bidding Documents. Such requests must be in writing and received by the Procuring Entity, either at its given address or through electronic mail indicated in the **IB**, at least ten (10) calendar days before the deadline set for the submission and receipt of Bids.

10. Documents comprising the Bid: Eligibility and Technical Components

- 10.1. The first envelope shall contain the eligibility and technical documents of the Bid as specified in Section VIII (Checklist of Technical and Financial Documents).
- 10.2. The Bidder's SLCC as indicated in **ITB** Clause 5.3 should have been completed within **the past two (2) years** prior to the deadline for the submission and receipt of bids.
- 10.3. If the eligibility requirements or statements, the bids, and all other documents for submission to the BAC are in foreign language other than English, it must be accompanied by a translation in English, which shall be authenticated by the appropriate Philippine foreign service establishment, post, or the equivalent office having jurisdiction over the foreign bidder's affairs in the Philippines. Similar to the required authentication above, for Contracting Parties to the Apostille Convention, only the translated documents shall be authenticated through an apostille pursuant to GPPB Resolution No. 13-2019 dated 23 May 2019. The English translation shall govern, for purposes of interpretation of the bid.

11. Documents comprising the Bid: Financial Component

- 11.1. The second bid envelope shall contain the financial documents for the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.
- 11.2. If the Bidder claims preference as a Domestic Bidder or Domestic Entity, a certification issued by DTI shall be provided by the Bidder in accordance with Section 43.1.3 of the 2016 revised IRR of RA No. 9184.
- 11.3. Any bid exceeding the ABC indicated in paragraph 1 of the **IB** shall not be accepted.
- 11.4. For Foreign-funded Procurement, a ceiling may be applied to bid prices provided the conditions are met under Section 31.2 of the 2016 revised IRR of RA No. 9184.

12. Bid Prices

12.1. Prices indicated on the Price Schedule shall be entered separately in the following manner:

IB-2023-089 to 090 : Various Supplies CY 2023

- a. For Goods offered from within the Procuring Entity's country:
 - i. The price of the Goods quoted EXW (ex-works, ex-factory, exwarehouse, ex-showroom, or off-the-shelf, as applicable);
 - ii. The cost of all customs duties and sales and other taxes already paid or payable;
 - iii. The cost of transportation, insurance, and other costs incidental to delivery of the Goods to their final destination; and
 - iv. The price of other (incidental) services, if any, listed in e.
- b. For Goods offered from abroad:
 - i. Unless otherwise stated in the **BDS**, the price of the Goods shall be quoted delivered duty paid (DDP) with the place of destination in the Philippines as specified in the **BDS**. In quoting the price, the Bidder shall be free to use transportation through carriers registered in any eligible country. Similarly, the Bidder may obtain insurance services from any eligible source country.
 - ii. The price of other (incidental) services, if any, as listed in **Section VII (Technical Specifications).**

13. Bid and Payment Currencies

- 13.1. For Goods that the Bidder will supply from outside the Philippines, the bid prices may be quoted in the local currency or tradeable currency accepted by the BSP at the discretion of the Bidder. However, for purposes of bid evaluation, Bids denominated in foreign currencies, shall be converted to Philippine currency based on the exchange rate as published in the BSP reference rate bulletin on the day of the bid opening.
- 13.2. Payment of the contract price shall be made in:
 - a. Philippine Pesos.

14. Bid Security

- 14.1. The Bidder shall submit a Bid Securing Declaration¹ or any form of Bid Security in the amount indicated in the **BDS**, which shall be not less than the percentage of the ABC in accordance with the schedule in the **BDS**.
- 14.2. The Bid and bid security shall be valid until *120 calendar days*. Any Bid not accompanied by an acceptable bid security shall be rejected by the Procuring Entity as non-responsive.

15. Sealing and Marking of Bids

Use of indelible ink <u>color blue</u> shall be used by the authorized signatory in signing the required forms. *Strictly NO using of staple wire and thick materials for tab*

IB-2023-089 to 090 : Various Supplies CY 2023

The **First (1st) Envelope**, shall contain the following <u>Technical Documents</u> accomplished in one (1) set, each set filed in a folder

The Second (2nd) Envelope shall contain the Financial Component accomplished in two (2) sets, each set filed in a folder including the USB Flash Drive (Section VIII. Checklist (Financial Component Envelope No. 2. Note)

All copies should be certified as true copy

| COLOR CODING OF | RED – Pharmaceutical | |
|-------------------|------------------------------|--|
| FOLDERS/ENVELOPES | YELLOW GOLD – Direct Medical | |

LABEL ON THE ENVELOPE/S:

Name of PROCURING ENTITY Name of CONTRACT TO BE BID IB Number DATE of Bid Opening Name of the Bidder Company Address of the Bidder Company

IDENTIFY THE ENVELOPES:

- as: > Technical Component Requirements for PHARMA (original and copy 1) for DIRECT MEDICAL (original)
 - > Financial Component Requirement (original, copy 1 & 2)

16. Deadline for Submission of Bids

16.1. The Bidders shall submit on the specified date and time and either at its physical address or through online submission as indicated in paragraph 7 of the **IB**.

17. Opening and Preliminary Examination of Bids

17.1. The BAC shall open the Bids in public at the time, on the date, and at the place specified in paragraph 9 of the **IB**. The Bidders' representatives who are present shall sign a register evidencing their attendance. In case videoconferencing, webcasting or other similar technologies will be used, attendance of participants shall likewise be recorded by the BAC Secretariat.

In case the Bids cannot be opened as scheduled due to justifiable reasons, the rescheduling requirements under Section 29 of the 2016 revised IRR of RA No. 9184 shall prevail.

17.2. The preliminary examination of bids shall be governed by Section 30 of the 2016 revised IRR of RA No. 9184.

18. Domestic Preference

18.1. The Procuring Entity will grant a margin of preference for the purpose of comparison of Bids in accordance with Section 43.1.2 of the 2016 revised IRR of RA No. 9184.

19. Detailed Evaluation and Comparison of Bids

- 19.1. The Procuring BAC shall immediately conduct a detailed evaluation of all Bids rated "passed," using non-discretionary pass/fail criteria. The BAC shall consider the conditions in the evaluation of Bids under Section 32.2 of the 2016 revised IRR of RA No. 9184.
- 19.2. If the Project allows partial bids, bidders may submit a proposal on any of the lots or items, and evaluation will be undertaken on a per lot or item basis, as the case maybe. In this case, the Bid Security as required by **ITB** Clause 15 shall be submitted for each lot or item separately.

IB-2023-089 to 090 : Various Supplies CY 2023

Section II. Instructions to Bidder

- 19.3. The descriptions of the lots or items shall be indicated in **Section VII** (**Technical Specifications**), although the ABCs of these lots or items are indicated in the **BDS** for purposes of the NFCC computation pursuant to Section 23.4.2.6 of the 2016 revised IRR of RA No. 9184. The NFCC must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder.
- 19.4. The Project shall be awarded as follows:
 - Option 3 One Project having several items, which shall be awarded as separate contracts per item.
- 19.5. Except for bidders submitting a committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation, all Bids must include the NFCC computation pursuant to Section 23.4.1.4 of the 2016 revised IRR of RA No. 9184, which must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder. For bidders submitting the committed Line of Credit, it must be at least equal to ten percent (10%) of the ABCs for all the lots or items participated in by the prospective Bidder.

20. Post-Qualification

20.2. Within a non-extendible period of five (5) calendar days from receipt by the Bidder of the notice from the BAC that it submitted the Lowest Calculated Bid, the Bidder shall submit its latest income and business tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) and other appropriate licenses and permits required by law and stated in the **BDS**.

21. Signing of the Contract

CONFORME.

21.1. The documents required in Section 37.2 of the 2016 revised IRR of RA No. 9184 shall form part of the Contract. Additional Contract documents are indicated in the **BDS**.

| CONFORME. | |
|--|-----------------------------------|
| Authorized Signatory | |
| Signature over printed name | |
| Contact Number: | |
| Name of Company/Firm | |
| C 2 000 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | |
| Company's Official E-mail Address (where notices will be sent) | Company's Official Contact Number |

Section II. Instructions to Bidder



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER

Bids and Awards Committee

Quezon Avenue, Quezon City 1100 website: www.pcmc.gov.ph email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION III

Bid Data Sheet

Supply and Delivery of Various Supplies for CY 2023

Bid Data Sheet

| ITB Clause | | | | |
|------------|---|---|---------------------------|----------------------------|
| 5.3 | | contracts similar to the Project sh nd delivery of: | all be: | |
| | Various Pharm | naceutical Supplies CY 2023 | Various Pharma | aceutical Supplies |
| | Various Direct | Medical Supplies CY 2023 | Various Med | dical Supplies |
| | b. completed of bids. | d within the last two (2) years pr | ior to the deadline for t | he submission and receipt |
| 7.1 | Subcontracting is | not allowed. | | |
| 12 | The Bid prices for Pesos. | Goods supplied from outside of | the Philippines shall be | quoted in Philippine |
| 14.1 | | hall be in the form of a Bid Secur | ring Declaration, or any | of the following forms |
| | security is in credit; or 2. The amoun | of not less than two percent (no cash, cashier's/manager's check to find less than five percent of Surety Bond. | ck, bank draft/guarante | e or irrevocable letter of |
| 19.3 | , , , | ery of the following: | | |
| | IB NUMBER | ITEM DESCRI | PTION | TOTAL ABC |
| | IB I (CIVIBEIC | Supply and Delivery of: | 11011 | TOTALLABO |
| | IB-2023-089 | Various Pharmaceutical Supp | olies CY 2023 | 112,508,915.79 |
| | IB-2023-090 | Various Direct Medical Supp | olies CY 2023 | |
| | | A. Nephrology and Hemod | ialysis Supplies | 2,776,480.00 |
| | | B. Pediatric Cardiology Su | pplies | 4,236,413.72 |
| | | C. Pediatric Surgery Suppl | ies | 2,277,889.56 |
| | | D. Perinatology Supplies | | 1,313,123.44 |
| 20.2 | | ulated Bidder shall submit the foll of <i>five (5) calendar days</i> from re | | |
| | | come and Business Tax Returns (FPS) within the last three (3) more | _ | he BIR Electronic |
| | numbers | e of Performance in letterhead and email addresses signed by th clients of the bidder issued with | e authorized head of the | e Department from |
| | Note: | Certification issued by PCMC – included if bidder had done be should be of same category (e bided. | ousiness with us. Certi | fication of which |
| | Security | tion Certificate from the Depar and Exchange Commission (S laws of the Philippines. | | • ` ' |

| | place of bu | usiness permit issued by the city or musiness of the prospective bidder is loc Economic Zones or Areas. | |
|---------------------------|--|---|---|
| | | Audited Financial Statements and Inthrough the BIR Electronic Filing and | |
| | 6. Valid and Administra | current License to Operate (LTO) tion (FDA) | issued by Food and Drug |
| | 7. Section II. | Instructions to Bidders with signature (con | nforme) on all pages |
| | 8. Section III. | Bid Data Sheet with signature (conforme |) on all pages |
| | 9. Section IV. | General Conditions of the Contract with | signature (conforme) on all pages |
| | 10. Section V. | Special Conditions of the Contract with si | ignature (conforme) on all pages |
| | 11. Certificatio is required | on for Assurance of Stocks Availability [u] | se of Form No. DOBA–PCMC–CAF10 |
| | 12. Return Poli | cy [use of Form No. DOBA – PCMC – C | RF34 is required] |
| | copy of cer | rer's Certification or if the Bidder is not a tification from the manufacturer as autho- ne products/items | |
| | 14. Valid and Administra | current Certificate of Product Registr tion (FDA) | ation issued Food and Drugs |
| | | ufacturer and/or products certification body (ISO 14020, 14021, 14024, 14025 or | • |
| | where the | guidelines regarding disposal of the suppl used/decommissioned products/ packag nd/or disposal e.g. buy-back program) | |
| | 17. Other appropriate Documents | opriate licenses and permits required by | law and stated in the Bidding |
| | finding against the disqualify the Bidde Note: Requirement | t Nos. 13 to 16 for items JOINED must | orfeiture of the bid security and |
| | | y Sheet to be provided by PCMC. | |
| 21.2 | No additional contr | ract documents relevant to the Project | |
| CONFOR | ME: | | |
| Authorized Signature o | Signatory ver printed name | Contact No: | |
| Name of Co | ompany/Firm | Company's Official Email Address | Company's Official Contact No. |
| 1 10111C 01 C | | (where notices will be sent) | Company 5 Official Comact No. |



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER

Bids and Awards Committee

Quezon Avenue, Quezon City 1100 website: www.pcmc.gov.ph email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION IV

General Conditions of Contract

Supply and Delivery of Various Supplies for CY 2023

1. Scope of Contract

This Contract shall include all such items, although not specifically mentioned, that can be reasonably inferred as being required for its completion as if such items were expressly mentioned herein. All the provisions of RA No. 9184 and its 2016 revised IRR, including the Generic Procurement Manual, and associated issuances, constitute the primary source for the terms and conditions of the Contract, and thus, applicable in contract implementation. Herein clauses shall serve as the secondary source for the terms and conditions of the Contract.

This is without prejudice to Sections 74.1 and 74.2 of the 2016 revised IRR of RA No. 9184 allowing the GPPB to amend the IRR, which shall be applied to all procurement activities, the advertisement, posting, or invitation of which were issued after the effectivity of the said amendment.

Additional requirements for the completion of this Contract shall be provided in the **Special Conditions of Contract (SCC).**

2. Advance Payment and Terms of Payment

- 2.1. Advance payment of the contract amount is provided under Annex "D" of the revised 2016 IRR of RA No. 9184.
- 2.2. The Procuring Entity is allowed to determine the terms of payment on the partial or staggered delivery of the Goods procured, provided such partial payment shall correspond to the value of the goods delivered and accepted in accordance with prevailing accounting and auditing rules and regulations. The terms of payment are indicated in the SCC.

[Include the following clauses if Framework Agreement will be used:]

- 2.3. For a single-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier in its bid.
- 2.4. For multi-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier during conduct of Mini-Competition.

3. Performance Security

Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than prior to the signing of the Contract by both parties, the successful Bidder shall furnish the performance security in any of the forms prescribed in Section 39 of the 2016 revised IRR of RA No. 9184. [Include if Framework Agreement will be used:] In the case of Framework Agreement, the Bidder may opt to furnish the performance security or a Performance Securing Declaration as defined under the Guidelines on the Use of Framework Agreement.}

4. Inspection and Tests

The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Project {[Include if Framework Agreement will be used:] or Framework Agreement} specifications at no extra cost to the Procuring Entity in accordance with the Generic Procurement Manual. In addition to tests in the SCC, Section IV (Technical Specifications) shall specify what inspections and/or tests the Procuring Entity requires, and where they are to be conducted. The Procuring Entity shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

All reasonable facilities and assistance for the inspection and testing of Goods, including access to drawings and production data, shall be provided by the Supplier to the authorized inspectors at no charge to the Procuring Entity.

5. Warranty

- 6.1. In order to assure that manufacturing defects shall be corrected by the Supplier, a warranty shall be required from the Supplier as provided under Section 62.1 of the 2016 revised IRR of RA No. 9184.
- 6.2. The Procuring Entity shall promptly notify the Supplier in writing of any claims arising under this warranty. Upon receipt of such notice, the Supplier shall, repair or replace the defective Goods or parts thereof without cost to the Procuring Entity, pursuant to the Generic Procurement Manual.

6. Liability of the Supplier

The Supplier's liability under this Contract shall be as provided by the laws of the Republic of the Philippines.

If the Supplier is a joint venture, all partners to the joint venture shall be jointly and severally liable to the Procuring Entity.

| CONFORME: | |
|---|----------------------------|
| Authorized Signatory | |
| Signature over printed name | |
| Contact Number: | _ |
| Name of Company/Firm | |
| Company's Official E-mail Address Number | Company's Official Contact |



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER

Bids and Awards Committee

Quezon Avenue, Quezon City 1100 website: www.pcmc.gov.ph email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION V

Special Conditions of Contract

Supply and Delivery of Various Supplies for CY 2023

Special Conditions of Contract

| | Special Conditions of Contract |
|---------------|--|
| GCC Clause | |
| | For Goods supplied from within the Philippines: |
| | Upon delivery of the Goods to the Project Site, the Supplier shall notify the Procuring Entity and present the following documents to the Procuring Entity: |
| | (i) Original and four copies of the Supplier's invoice/delivery receipt showing Goods' description, quantity, unit price, and total amount; |
| | (ii) Four copies of Material Safety Data Sheet for a specified product upon initial delivery |
| | Packaging – |
| | The Supplier shall provide such packaging of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in this Contract. The packaging shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packaging case size and weights shall take into consideration, where appropriate, the remoteness of the Goods' final destination and the absence of heavy handling facilities at all points in transit |
| | The packaging, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, specified below, and in any subsequent instructions ordered by the Procuring Entity. |
| | The Supplier shall have an established disposal and retrieval program or take back system for their products (items with container) 1 The Supplier shall submit MSDS for a specified product. 2. The product label shall bear the following information: a. Product specifications and ingredients b. Manufacturing and Expiration Dates c. Precautions d. Instructions for proper use and disposition e. Hazardous items shall be properly labeled as a hazardous product (e.g. flammable cytotoxic, radioactive, poison, etc.) |
| | 3.The product shall not contain halogenated plastics and PVCs.4.The product shall be packed in suitable packaging materials which are reusable and recyclable. |
| | Transportation – |
| | Where the Supplier is required under Contract to deliver the Goods CIF, CIP, or DDP, transport of the Goods to the port of destination or such other named place of destination in the Philippines, as shall be specified in this Contract, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price. |
| | Where the Supplier is required under this Contract to transport the Goods to a specified place of destination within the Philippines, defined as the Project Site, transport to such place of destination in the Philippines, including insurance and storage, as shall be specified in this Contract, shall be arranged by the Supplier, and related costs shall be included in the contract price. |

| | Where the Supplier is required under Contract to deliver the Goods CIF, CIP or DDP, Goods are to be transported on carriers of Philippine registry. In the event that no carrier of Philippine registry is available, Goods may be shipped by a carrier which is not of Philippine registry provided that the Supplier obtains and presents to the Procuring Entity certification to this effect from the nearest Philippine consulate to the port of dispatch. In the event that carriers of Philippine registry are available but their schedule delays the Supplier in its performance of this Contract the period from when the Goods were first ready for shipment and the actual date of shipment the period of delay will be considered force majeure. |
|-------------------------|---|
| | The Procuring Entity accepts no liability for the damage of Goods during transit other than those prescribed by INCOTERMS for DDP deliveries. In the case of Goods supplied from within the Philippines or supplied by domestic Suppliers risk and title will not be deemed to have passed to the Procuring Entity until their receipt and final acceptance at the final destination. |
| | Intellectual Property Rights – |
| | The Supplier shall indemnify the Procuring Entity against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof. |
| 2.2 | The terms of payment shall be on Acceptance: |
| | 100% of the Contract Price per Delivery Order Slip shall be paid to the Supplier within 30 to 45 days or Supplier's credit term after final acceptance and submission of required documents. |
| 3 | Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than prior to the signing of the Contract by both parties, the successful Bidder shall furnish the performance security. |
| 4 | The inspections and tests that will be conducted are: 1) Upon delivery, the Goods shall undergo preliminary physical inspection by the Inspection Team of the PROCURING ENTITY to ascertain the physical condition and acceptability of the Goods. |
| | 2) The supplier shall promptly replace the equivalent quantity of Goods taken as samples without cost to the PROCURING ENTITY |
| 5 | Three (3) months after acceptance by the Procuring Entity of the delivered Goods or after the Goods are consumed, whichever is earlier. |
| | Winning bidder has to choose the form of retention money required of under R.A 9184 Sec. 62.1 |
| | The said amount shall only be released after the lapse of the warranty period specified in Section VII Technical Specification; provided, however, that the Supplies delivered are free from patent and latent defects and all the conditions imposed under this Contract have been fully met. |
| CONFORM | IE: |
| | Contact Number: |
| Authorized Signature ov | Signatory er printed name Name of Company/Firm |
| -0 | 1 |
| Company's (| Official E-mail Address Company's Official Contact Number |



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Pids and Awards Committee

Bids and Awards Committee

Quezon Avenue, Quezon City 1100 website: www.pcmc.gov.ph email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION VI

Schedule of Requirements

Supply and Delivery of Various Supplies for CY 2023

The delivery schedule expressed as weeks/months stipulates hereafter a delivery date which is the date of delivery to the project site.

| Description | Total ABC (Php) | Delivery Site | PCMC Requirement DELIVERY PERIOD |
|--|--------------------|---------------|---|
| Various Pharmaceutical Supplies | 112,508,915.79 | Materials | |
| Various Direct Medical Supplies CY 2023 | | Management | Within seven (7) |
| A. Nephrology and Hemodialysis Supplies | 2,776,480.00 | PUMC, | working days from receipt of |
| B. Pediatric Cardiology Supplies CY 2023 | 4,236,413.72 | | DELIVERY ORDER SLIP |
| C. Pediatric Surgery Supplies (Re-bid) | 2,277,889.56 | | ORDER SEIF |
| D. Perinatology Supplies (Re-bid) | 1,313,123.44 | Quezon City | |

DELIVERY AND ACCEPTANCE

- > Staggered delivery and staggered payment
- > Supplies to be delivered should have an expiration at least one (1) year and longer or as expressed/required by the end-user.
- > The Supplier should submit Materials Safety Data Sheet upon initial delivery, if applicable.
- The supplier should deliver the goods called for in the Purchase Order (PO) within seven (7) working days or as stated on Delivery Period upon receipt of approved Delivery Order Slip, faxed or personally received during office hours at the Materials Management Division.
- All goods delivered pursuant to the Purchase Order (PO) with Delivery Order Slip shall be subject to acceptance and inspection by the end-user as well as by the House Inspector and of the Resident Auditor or their representatives. Goods delivered not in conformity with specifications shall be rejected and the contractor held in default.

| CONFORME: | |
|--|-----------------|
| NAME OF COMPANY | ADDRESS |
| SIGNATURE OVER PRINTED NAME OF AUTHORIZED REPRESENTATIVE | TELEPHONE / FAX |



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Pids and Awards Committee

Bids and Awards Committee

Quezon Avenue, Quezon City 1100 website: www.pcmc.gov.ph email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION VII

Technical Specifications

Supply and Delivery of Various Supplies for CY 2023

PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City

TERMS OF REFERENCE

CY 2023

HAZARDOUS PHARMACEUTICALS

- The winning bidders for hazardous pharmaceuticals (see attached list) shall provide PCMC two copies (one for Property and Supply and one for the Pharmacy Division) of the corresponding Materials Safety Data Sheet (MSDS) of said medicine/galenicals upon delivery.
- The supplier shall make sure that these pharmaceuticals are properly packed for safety from breakage and spills upon delivery to PCMC. Likewise, these pharmaceuticals shall be properly labeled as a hazardous product (e.g., flammable, cytotoxic, radioactive, poison.etc.).
- Suppliers shall provide the PCMC with the appropriate Spill Kit upon the request of the Pharmacy Division for use in the wards/clinical areas using these products.
- 4. The supplier shall be responsible in disposing the expired and defective hazardous pharmaceuticals. The Pharmacy Division shall inform the corresponding supplier three months before the expiry date of their product. The supplier shall be informed about the defective products as soon as it has been detected.
- Upon request of the corresponding end-user, the supplier shall provide training on safe handling of their product(s), including management of spills.

| CONFORME: | | |
|--|----------------------------------|--------------------------------|
| Authorized Signatory Signature over printed name | Contact No: | |
| Name of Company/Firm (Where notices will be sent) | Company's Official Email Address | Company's Official Contact No. |

LIST OF HAZARDOUS PHARMACEUTICALS

- 1. Bleomycin Sulfate 15 mg inj.
- 2. Calcium Folinate 50 mg inj.
- 3. Carboplatin 150 mg vl.
- 4. Cisplatin 50 mg vl
- 5. Cyclophosphamide 200 mg and 500 mg vl
- 6. Cytarabine 100 mg, 500 mg, and 1 g vl.
- 7. Dactinomycin 500 mcg inj
- 8. Doxorubicin 10 mg, and 50 mg vl
- 9. Etoposide 20 mg/ml, 5 mL inj
- 10. Fluorouracil vl 500mg IV
- 11. Idarubicin HCl 5 mg inj.
- 12. Ifosfamide 1 g and 2 g vl
- 13. Irinotecan 100 mg/5mL and 40 mg/2mL (HCl) concentrate, vl (IV infusion)
- 14. L-asparaginase 10,000 IU vl
- 15. Mercaptopurine 50 mg tab
- 16. Methotrexate 500 mg, 1 g, and 50 mg vl; 2.5 mg tablet
- 17. Mitoxanthrone 20 mg Inj.
- 18. Paclitaxel 6mg/mL 17mL (IV) vl
- 19. Rituximab 500mg inj. 50mL vial and 100mg inj. 10mL vial
- 20. Vinblastine 10 mg Inj
- 21. Vincristine 1 mg and 2 mg inj.
- 22. Povidone Iodine solution (all dosage preparations)
- 23. Gadoteric acid (all dosage preparations)
- 24. Gadobutrol (all dosage preparations)
- 25. Iohexol (all dosage preparations)
- 26. Ioversol (all dosage preparations)
- 27. Iopamidol (all dosage preparations)
- 28. Iopromide (all dosage preparations)
- 29. Sevoflurane Inhalation 250 mL

| CONFORME: | | |
|--|----------------------------------|--------------------------------|
| Authorized Signatory Signature over printed name | Contact No: | |
| Name of Company/Firm (Where notices will be sent) | Company's Official Email Address | Company's Official Contact No. |

PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City

TERMS OF REFERENCE CY 2023

Pharmaceutical Products, Containers, and Devices

The following are the requirements to winning suppliers in compliance with Administrative Order No. 2019-0041, dated October 4, 2019 re: Implementing Guidelines in Assuring the Efficacy, Quality, and Safety of Pharmaceutical Products in the Public Health Facilities;

 All pharmaceutical products and devices shall be of fresh commercial stock as reflected in the Certificate of Product Registration (CPR) issued by the FDA upon delivery. The acceptable shelf life upon delivery is as follows:

| Claimed Shelf Life in CPR | Minimum Remaining Shelf Life Upon Delivery |
|---------------------------|--|
| 60 months | 42 - 60 months |
| 48 months | 34 – 48 months |
| 36 months | 30 - 36 months |
| 24 months | 18 – 24 months |
| 18 months | 12 – 18 months |
| 12 months | 12 months |

- 2. The CPR must be valid for the entire period of the award. If the CPR is about to expire, the supplier must have submitted a copy of an application of renewal to the FDA at least 3 months before the expiry date (a copy of the expiring CPR which is stamped with an "extension of validity" shall be submitted as proof).
- The Pharmacist-in-charge of inspection and acceptance of pharmaceutical products and devices shall conduct random sampling of the products delivered for batch testing.
 - 3.1 The samples collected shall be submitted to FDA for test analysis. The Pharmacist shall determine the kind of test(s) to be done based on the physical inspection done. (Annex A)
 - 3.2 The supplier shall replace (same batch) or pay the cost of the samples collected for testing.
 - 3.3 The supplier shall pay the cost of testing of the products collected.
- 4. The supplier shall be provided with a copy of the result of tests analysis done on their products.
- 5. The supplier shall submit the batch notification for antibiotic products and batch certificate for vaccines issued by the FDA upon delivery.

| 6. The performance of the suppliers shall be monitored based on the following Key Performance Indicators: |
|--|
| 6.1 Suppliers meet quality and service standards specified in the Terms of Reference (TOR)/Purchase Order (PO)/Contract |
| 6.2 Timeliness of delivery |
| 6.3 Completeness of quantity delivered |
| 6.4 Zero defects of products |
| 6.5 Relevant additional services provided (e.g. disposal, recall) |
| |
| CONFORME: |
| Authorized Signatory Contact No: Signature over printed name |
| Name of Company/Firm (Where notices will be sent) Company's Official Email Address Company's Official Contact No. |

¥

.

ANNEX A

Minimum Number of Sample Units Required for Each Test Analysis (FDA Circular No. 2014-014 dated 16 March 2014)

PHARMACEUTICAL PRODUCTS

a. Microbiological Tests

| Sample Type | Test Parameter | Number of Sample Units |
|--|---|--|
| Nonaqueous/aqueous preparation for oral use | Total Aerobic Microbial Count Total Combined Yeast & Mold Count Absence of Escherichia coli in 1g or mL | Minimum of 2 commercial presentations with a |
| Rectal Usc | Total Aerobic Microbial count Total Combined Yeast & Mold Count Total Combined Yeast & Mold Count | total net weight or volume of not less |
| Oromucosal/Gingival/ Cutaneous/Nasal/Auri cular use | Total Aerobic Microbial Count Total Combined Yeast & Mold Count Absence of Staphylococcus aureus in 1g or mL Absence of Pseudomonas Aeroginosa in 1 g or mL | than 50g or mL |
| Inhalation use (special requirements apply to liquid preparations for nebulization) | Total Aerobic Microbial Count Total Combined Yeast & Mold Count Absence of Staphylococcus aureus in 1g or ml. Absence of bile-tolerant Gram-negative bacteria in 1 g or ml. | |

b. Biological Tests

| Sample Type | Test Parameter | Number of Sample Units |
|--|--------------------------|-------------------------|
| Liquid Preparations 1mL to 100mL More than 100mL | Bacterial endotoxin test | 20 bottles 6 bottels |
| 1mL to 100mL 500 to 1000mL | Sterility Test | 20 bottles 6 bottles |
| Solid Preparations | Sterility Test | 20 units |

c. Physico-chemical Tests

| Sample Type | Test Parameter | Number of Sample Units | |
|---|---|---|--|
| Tablet/Capsule | Assay/Potency Dissolution Uniformity of Dosage Units Identification Test Disintegration Tablet hardness | 60 tablets/capsules 50 tablets/capsules 40 tablets/capsules 20 tablets/capsules 20 tablets/capsules 10 tablets/capsules | |
| Granules/Powder for Suspension/Syrup | Assay and Minimum Fill pH Identification Test | 10 bottles 2 bottles 3 bottles | |
| Injectables (lmL to 2mL) | Assay/Potency pH | 20 vials/ampules 10 vials/ampules | |
| Injectables (5mL to 10mL) | | 20 vials/ampules 5 vials/ampules | |
| Injectables (20mL to 100mL) | | 10 vials/ampules 2 vials/ampules | |
| Ointment/Cream/Gel | Assay/Potency | 10 tubes | |
| Aerosol | 20 2 | 10 pressurized cans 30 pieces | |
| Suppositories | | | |

PHARMACEUTICAL CONTAINERS

| Sample Type | Test Parameter | Number of Sample Units |
|--|---|---|
| Plastic container for suspension/syrup, oral preparations a. 10 mL b. 30 to 60 mL c. 60 to 100mL d. 250 mL c. 500 to | Residue on Ignition Lead Buffering Capacity | 120 pcs 60 pcs 40 pcs 20 pcs 10 pcs |
| Plastic bottles/TV infusion a. 100mL b. 250mL c. 500 to 1000mL | | 15 pcs 10 pcs 6 pcs |
| Polyampules a. 1 to 2 mL b. 3 to 5 mL c. 6 to 10 mL | | 300 pcs 250 pcs 200 pcs |
| Vials a. 10 mL b. 20 to 25 mL c. 30 to 50 mL | | 120 pcs 60 pcs 30 pcs |
| Caps (Diameter) a. <0.5 cm b. Between 1 c 2.5 cm c. > 2.5 cm | | 800 pcs 48 pcs 30 pcs |

DEVICES

| Sample Type | Test Parameter | Number of Sample Units |
|-----------------|---|------------------------|
| Medical Devices | Bacterial endotoxin test Sterility Test | 20 units 20 units |

| CONFORME: | | |
|---|----------------------------------|--------------------------------|
| Authorized Signatory Signature over printed name | Contact No: | |
| Name of Company/Firm (Where notices will be sent) | Company's Official Email Address | Company's Official Contact No. |

PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City

TERMS OF REFERENCE

CY 2023

1. LABELLING:

For each vial, box, carton, and corrugated carton, the following should be legibly printed:

"Philippine Government Property"

Department of Health

NOT FOR SALE

- 2. Drugs and medicines delivered are subject to random sampling for submission to Food and Drug Administration (FDA) or any FDA Accredited testing laboratories. Samples are for testing to qualify and conform to label claim. Testing fee and replacement of sampled quantities shall be at the Supplier's expense. Number of samples for testing see Administrative Order No. 2019-0041 "Implementing Guidelines in Assuring the Efficacy, Quality, and Safety of Pharmaceutical Products in the Public Health Facilities".
- 3. Drugs and medicines that will not conform with the standard specification shall be returned to the Supplier and shall not be paid by PCMC.
- 4. Drugs and medicines with Adverse Drug Event/Reaction (ADE/ADR) findings shall be reported to FDA. Remaining stocks shall be returned to the Supplier for replacement with another batch within 7 working days from pull out. For the 2nd offense, remaining stocks shall be returned to the Supplier without replacement and shall not be paid by PCMC. The succeeding order/request shall be awarded to the next Lowest Calculated and Responsive Bidder.
- 5. All pulled-out for any various reasons shall be issued a credit memo by the Supplier. Such items shall be replaced by the Supplier within one (1) month otherwise the corresponding amount shall be deducted from any amount due to the Supplier.
- 6. The winning bidders for hazardous pharmaceuticals (see attached list) shall provide PCMC two copies (one for Materials Management Division and one for the Pharmacy Division) of the corresponding Materials Safety Data Sheet (MSDS) of said medicine upon delivery.
- 7. The supplier shall make sure that these pharmaceuticals are properly packed for safety from breakage and spills upon delivery to PCMC. Likewise, these pharmaceuticals shall be properly labeled as a hazardous product (e.g., cytotoxic).
- 8. Suppliers shall provide the PCMC with the appropriate Spill Kit upon the request of the Pharmacy Division for use in the wards/clinical areas using these products. It shall be replaced once used.
- 9. The supplier shall be responsible for disposing of the expired and defective hazardous pharmaceuticals. The Pharmacy Division shall inform the corresponding supplier three months before the expiry date of their product. The supplier shall be informed about the defective products as soon as they have been detected.

10. The winning supplier shall provide training on safe handling of their product(s), including management of spills.

LIST OF HAZARDOUS PHARMACEUTICALS

- 1. Bleomycin Sulfate 15 mg injection
- 2. Calcium Folinate 50 mg injection
- 3. Carboplatin 150 mg and 450 mg vial
- 4. Cisplatin 10 mg and 50 mg vial
- 5. Cyclophosphamide 500 mg vial
- 6. Cytarabine 100 mg, 500 mg, and 1 g vial
- 7. Dacarbazine 200 mg vial
- 8. Dactinomycin 500 mcg injection
- 9. Doxorubicin 10 mg, and 50 mg vial
- 10. Etoposide 20 mg/ml, 5 mL injection
- 11. Fluorouracil vl 500 mg IV
- 12. Idarubicin HCl 5 mg inj.
- 13. Ifosfamide 1 g and 2 g vl
- 14. Imatinib 100 mg tablet
- 15. Irinotecan 100 mg/5mL and 40 mg/2mL (HCl) concentrate, vial
- 16. L-asparaginase 10,000 IU vial
- 17. Mercaptopurine 50 mg tablet
- 18. Methotrexate 1 g, and 50 mg vial; 2.5 mg tablet
- 19. Rituximab 500mg inj. 50mL vial and 100mg inj. 10mL vial
- 20. Sirolimus 0.5 mg and 1 mg tablet
- 21. Vinblastine 10 mg Inj
- 22. Vincristine 1 mg and 2 mg inj.

| CONFORME: | | |
|---|--------------------------------|--|
| Authorized Signatory Signature over printed name | Contact No: | |
| Name of Company/Firm | | |
| Company's Official Email Address (where notices will be sent) | Company's Official Contact No. | |

PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City

Name of Project: VARIOUS PHARMACEUTICAL SUPPLIES
Total ABC = Php34,795,547.48

Invitation to Bid No. IB 2023-089 A

| | PCMC's REQUIREMENT BIDDER'S OFFER | | | | | | |
|------|-----------------------------------|--------|------|--|---|-------|--------------|
| Iten | Item No. Qty Unit | | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER |
| A | 1 | 700 | tab | Acetazolamide tab 250mg blister/foil pack | | | |
| A | 2 | 3,500 | amp | Acetylcysteine amp 100mg/mL 3mL (IMIV) | | | |
| A | 3 | 400 | tab | Aciclovir Sod tab 800mg | | | |
| A | 4 | 1,100 | vl | Aciclovir Sod vl 25mgmL, 10mL (IV inf) | | | |
| A | 5 | 30 | vl | Adenosine vl 3mg/mL, 2mL (IV) | | | |
| A | 6 | 2,500 | tab | Allopurinol tab 100mg blister/foil pack | | | |
| A | 7 | 512 | bt | AIOH MgOH susp bt 225+200mg/5mL, 120mL | | | |
| A | 8 | 30 | amp | Amiodarone HCl amp 50mg/mL, 3mL (IV) | | | |
| A | 9 | 4,500 | cap | Amoxicillin Trihyd cap 500mg blister/foil pack | | | |
| A | 10 | 300 | bt | Amoxicillin Trihyd susp bt 100mg/mL, 15mL | | | |
| A | 11 | 280 | bt | Amoxicillin Trihyd susp bt 250mg/5mL, 60mL | | | |
| A | 12 | 2,500 | vl | Ampicillin Sod 500mg + Sulbactam 250mg vl (IM,IV) | | | |
| A | 13 | 456 | bt | Ascorbic Acid drp bt 100mg/mL, 15mL | | | |
| A | 14 | 3,500 | bt | Ascorbic Acid syr bt 100mg/5mL, 120mL | | | |
| A | 15 | 60,000 | tab | Ascorbic Acid tab 500mg blister/foil pack | | | |
| A | 16 | 2,200 | amp | Atropine Sulf amp 1mg/mL, 1mL (IM,IV) | | | |
| A | 17 | 1,500 | tab | Azathioprine tab 50mg | | | |
| A | 18 | 200 | bt | Azithromycin susp 200mg/5mL 15 mL | | | |
| A | 19 | 6,000 | tab | Baclofen tab 10mg blister/foil pack | | | |
| A | 20 | 300 | supp | Bisacodyl Pedia supp 5mg | | | |
| Α | 21 | 100 | tab | Bisacodyl tab 5mg blister/foil pack | | | |

| | PCMC's REQUIREMENT | | | CMC's REQUIREMENT | BIDDER'S | OFFER | |
|------|--------------------|--------|--------|--|---|-------|--------------|
| Item | No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER |
| A | 22 | 24,000 | рс | Blood Sugar Strip | | | |
| A | 23 | 90 | рс | Budesonide+Formoterol 160/4.5mcg, 60doses | | | |
| Α | 24 | 100 | amp | Bupivacaine HCl in 8% Dextrose (heavy) amp 0.5%, 4mL, (spinal) | | | |
| Α | 25 | 300 | tab | Butamirate Citrate tab 50mg MR blister/foil pack | | | |
| Α | 26 | 6,000 | cap | Calcitriol cap 0.25mcg blister/foil pack | | | |
| A | 27 | 100 | amp/vl | Carbetocin amp/vl 100mcg (IV) | | | |
| Α | 28 | 600 | cap | Cefalexin Monohyd cap 500mg blister/foil pack | | | |
| A | 29 | 100 | bt | Cefalexin Monohyd drp bt 100mg/mL, 10mL | | | |
| A | 30 | 150 | bt | Cefalexin Monohyd syr/susp bt 250mg/5mL, 60mL | | | |
| A | 31 | 1,300 | vl | Cefazolin Sod vl 1g (IM,IV) | | | |
| A | 32 | 3,600 | vl | Ceftriaxone DiSod vl 1g + 10mL diluent (IV,IM) | | | |
| A | 33 | 200 | bt | Cefuroxime susp bt 125mg/5mL, 70mL | | | |
| A | 34 | 600 | bt | Cefuroxime susp bt 250mg/5mL, 50mL | | | |
| Α | 35 | 1,000 | cap | Celecoxib cap 100mg blister/foil pack | | | |
| A | 36 | 2,000 | cap | Celecoxib cap 200mg blister/foil pack | | | |
| A | 37 | 150 | bt | Cetirizine Dihydrochloride drp bt 2.5mg/mL 10mL | | | |
| A | 38 | 8,000 | tab | Ciprofloxacin HCl tab 500mg blister/foil pack | | | |
| A | 39 | 3,020 | vl | Ciprofloxacin Lactate vl 2mg/mL, 100mL (IV inf), sealed rubber cap | | | |
| A | 40 | 150 | bt | Clarithromycin susp bt 250mg/5mL gran 50mL | | | |
| A | 41 | 800 | amp | Clindamycin PO4 amp 150mg/mL 4mL (IM,IV) | | | |
| A | 42 | 100 | tbe | Clotrimazole 1% cream 10g | | | |
| A | 43 | 200 | bt | Cloxacillin Sod syr/susp bt 250mg/5mL, 60mL | | | |

| | PCMC's REQUIREMENT | | | CMC's REQUIREMENT | BIDDER'S OFFER | | |
|------|--------------------|--------|----------|--|---|-------|--------------|
| Item | No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER |
| Α | 44 | 2,000 | bt | Cotrimoxazole susp bt 200mg + 40mg/5mL, 60mL / 70mL | | | |
| Α | 45 | 2,800 | bt | Cotrimoxazole susp bt 400mg + 80mg/5mL, 60mL | | | |
| Α | 46 | 16,000 | cap/ tab | Cotrimoxazole tab/cap 800mg + 160mg blister/foil pack | | | |
| A | 47 | 2,300 | tab | Deferasirox 250mg dispersible tablet | | | |
| A | 48 | 1,500 | tab | Deferasirox tab 180mg | | | |
| Α | 49 | 1,500 | tab | Deferasirox tab 90mg | | | |
| Α | 50 | 5,000 | tab | Deferiprone tab 500mg | | | |
| A | 51 | 20 | amp | Digoxin amp 250mcg/mL, 2mL (IM,IV) | | | |
| A | 52 | 5,000 | tab | Digoxin tab 250mcg | | | |
| A | 53 | 300 | bt | Diphenhydramine HCl AF syr bt 12.5mg/5mL, 60mL | | | |
| A | 54 | 1,000 | cap | Diphenhydramine HCl cap 25mg | | | |
| A | 55 | 1,500 | cap | Diphenhydramine HCl cap 50mg blister/foil pack | | | |
| Α | 56 | 240 | bt | Domperidone susp bt 1mg/mL, 60mL | | | |
| Α | 57 | 2,500 | tab | Domperidone tab 10mg blister/foil pack | | | |
| Α | 58 | 200 | tab | Erythromycin Stearate tab 500mg blister/foil pack | | | |
| A | 59 | 40 | vl | Esmolol HCl vl 100mg/mL, 10mL | | | |
| A | 60 | 1,050 | vl | Factor VIII Conc lyoph powd vl + diluent (IV) 100 IU/mL | | | |
| A | 61 | 1,000 | tab | Famotidine tab 20mg | | | |
| A | 62 | 280 | bt | Ferrous Salt soln bt drp 15mg/0.6mL 15mL | | | |
| A | 63 | 20,000 | cap/tab | Ferrous Salt+Folic Acid tab/cap/film coated tab blister/foil pack | | | |
| A | 64 | 1,000 | cap | Fluconazole cap 50mg blister/foil pack | | | |
| A | 65 | 50 | bt | Fluocinolone acetonide 250mcg + Neomycin Sulfate 3.5mg + Polymyxin B Sulfate Otic Drops | | | |

| | | | P | CMC's REQUIREMENT | BIDDER'S OFFER | | |
|------|-----|-------|---------|---|---|-------|--------------|
| Item | No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER |
| A | 66 | 2,000 | cap/tab | Folic Acid 5mg blister/foil pack | | | |
| Α | 67 | 250 | bt | Folic acid drp 2.5mg/mL | | | |
| Α | 68 | 250 | bt | Folic acid syr 5mg/mL | | | |
| A | 69 | 360 | supp | Glycerol Infant supp 1.9g | | | |
| A | 70 | 20 | рс | Hepatitis A Vaccine 80U/0.5mL | | | |
| A | 71 | 1,440 | vl | Hydrocortisone Sod Succ powd vl 100mg (IT,IM,IV) drypack | | | |
| A | 72 | 960 | vl | Hydrocortisone Sod Succ vl 250mg/2mL, w/ 2mL diluent (IV/IT) | | | |
| A | 73 | 70 | tbe | Hydrocortisone Valerate 1% cream 10g | | | |
| Α | 74 | 276 | bt | Hydrogen Peroxide bt 3% 120mL | | | |
| Α | 75 | 700 | tab | Hydroxychloroquine 200 mg tablet | | | |
| Α | 76 | 1,000 | tab | Ibuprofen tab 200mg blister/foil pack | | | |
| A | 77 | 1,000 | tab | Ibuprofen tab 400mg blister/foil pack | | | |
| A | 78 | 100 | vl | Immunoglobulin, Hepatitis B H vl 100IU 0.5mL | | | |
| Α | 79 | 1,100 | vl | Immunoglobulin, NH IGIV vl 2500mg (2.5g) | | | |
| Α | 80 | 300 | vl | Iodixanol 652mg/mL (320mg iodine), 50mL | | | |
| A | 81 | 120 | vl | Iohexol vl 300mg iodine/mL, 50mL | | | |
| Α | 82 | 500 | vial | Iopromide 300 mg/mL equiv. to 623 mg iodine, 50 mL Vial | | | |
| Α | 83 | 430 | vl | Ioversol 636 mg/mL (300mg/mL iodine) 50mL | | | |
| Α | 84 | 100 | vl | Ioversol 741 mg/mL (350mg/mL iodine) 50mL | | | |
| Α | 85 | 100 | amp | Iron sucrose 20 mg/mL, 5 mL ampule | | | |
| Α | 86 | 200 | bt | Lagundi syr bt 300mg/5mL, 60mL | | | |
| Α | 87 | 500 | tab | Lagundi tab 300mg blister/foil pack | | | |

| | PCMC'S REQUIREMENT | | | | BIDDER'S OFFER | | | |
|------|--------------------|--------|------|---|---|-------|--------------|--|
| Iten | n No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER | |
| A | 88 | 1,500 | cap | Lansoprazole cap 30mg FDT blister/foil pack | | | | |
| A | 89 | 950 | bt | Levetiracetam 100mg/mL Oral Solution, 300mL | | | | |
| A | 90 | 3,400 | vl | Levetiracetam 100mg/mL, 5mL vl concentrate solution of IV | | | | |
| A | 91 | 11,000 | tab | Levetiracetam 250 mg FCT | | | | |
| A | 92 | 500 | tab | Levofloxacin tab 500 mg | | | | |
| A | 93 | 2,000 | tab | Levothyroxin tab 100 mcg | | | | |
| A | 94 | 2,000 | tab | Levothyroxin tab 50 mcg | | | | |
| A | 95 | 2,500 | рс | Lubricating Jelly scht 5g | | | | |
| A | 96 | 300 | tbe | Lubricating Jelly tbe 82g (150g) | | | | |
| A | 97 | 50 | bt | Mebendazole susp bt 100mg/5mL, 60mL | | | | |
| A | 98 | 2,000 | vl | Meropenem Trihydrate vl 1g (IV) | | | | |
| A | 99 | 4,200 | tab | Mesalazine 500mg tab EC | | | | |
| A | 100 | 4,500 | tab | Methimazole 5mg tab | | | | |
| A | 101 | 100 | amp | Methylergometrine Maleate amp 200mcg/mL, 1mL (IM,IV) | | | | |
| A | 102 | 500 | vl | Methylprednisolone Sod Succ vl 500mg/7.7mL+diluent (IV) | | | | |
| A | 103 | 1,000 | tab | Metronidazole tab 500mg blister/foil pack | | | | |
| A | 104 | 1,000 | vl | Metronidazole vl 5mg/mL, 100mL (IV inf), sealed rubber cap | | | | |
| Α | 105 | 10 | bt | Mineral Oil 1L | | | | |
| A | 106 | 1,400 | tab | Montelukast Sodium chewable tab 5mg blister/foil pack | | | | |
| A | 107 | 424 | bt | Multivitamins drp bt 15mL | | | | |
| A | 108 | 200 | tbe | Mupirocin oint tube 2% 15g | | | | |
| A | 109 | 1,000 | amp | Nalbuphine HCl amp 10mg/mL, 1 mL preservative free (IM, IV, SC) | | | | |

| | | | P | PCMC's REQUIREMENT | BIDDER'S OFFER | | |
|------|-----|--------|----------|--|---|-------|--------------|
| Item | No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER |
| A | 110 | 800 | cap | Nitrofurantoin macrocrystals cap 100mg blister/foil pack | | | |
| A | 111 | 20 | bt | Oxymetazoline HCl nasal drp 0.025% 10mL | | | |
| A | 112 | 20 | bt | Oxymetazoline HCl nasal spray 0.05% 15mL | | | |
| Α | 113 | 1,200 | vl | Paracetamol 10mg/mL, 100mL Soln for infusion (IV) | | | |
| A | 114 | 712 | bt | Paracetamol Alcohol Free drp bt 100mg/mL, 15mL | | | |
| Α | 115 | 3,560 | bt | Paracetamol Alcohol Free syr/susp bt 250mg/5mL, 60mL | | | |
| Α | 116 | 600 | vl | Penicillin G Sod vl 1,000,000U (IM,IV) | | | |
| A | 117 | 120 | jar | Petroleum jelly 25g | | | |
| A | 118 | 30,000 | tab | Phenobarbital Sod tab 30mg (gr1/2) | | | |
| Α | 119 | 300 | amp | Phenytoin Sod amp 50mg/mL, 5mL (IV) | | | |
| Α | 120 | 6,500 | amp | Phytomenadione colloidal soln amp 10mg/mL, 1mL (IV,IM,SC) | | | |
| Α | 121 | 100 | pfs/vial | Pneumococcal Polyvalent Vaccine 25mcg/0.5mL sol for inj, 0.5mL pfs/vial (IM, SC) | | | |
| Α | 122 | 960 | bt | Povidone Iodine Antiseptic 10% 120mL spray bottle | | | |
| Α | 123 | 50 | bt | Povidone Iodine Oral Soln 1% bt 60mL | | | |
| Α | 124 | 1,500 | bt | Prednisone susp 10mg/5mL 60mL | | | |
| A | 125 | 3,000 | tab | Prednisone tab 10mg blister/foil pack | | | |
| A | 126 | 11,000 | tab | Prednisone tab 20mg blister/foil pack | | | |
| A | 127 | 1,500 | tab | Prednisone tab 5mg blister/foil pack | | | |
| A | 128 | 10 | bt | Proparacaine 0.5% eye drops solution, 5 mL bottle | | | |
| A | 129 | 600 | tab | Ranitidine HCl tab 150mg blister/foil pack | | | |
| A | 130 | 200 | рс | Salbutamol Inhaler 100mcg x 200 dose | | | |
| A | 131 | 11,000 | neb | Salbutamol Sulf nebul soln 1mg/mL, 2.5mL (monodose) | | | |

Name of Project : VARIOUS PHARMACEUTICAL SUPPLIES $Total\ ABC = Php34,795,547.48$ Invitation to Bid No. IB 2023-089 A

TECHNICAL SPECIFICATIONS

| PCMC's REQUIREMENT BIDDER'S OFFER | | | | | | | |
|-----------------------------------|---|---|--|--------------------------------|-----|-----|--|
| No. | Otv | | | ITEM DESCRIPTION BRAND MANUE | | | |
| 132 | 100 | | | (Specification, Packing, etc.) | | | |
| 133 | 80 | bt | Sevoflurane inhalation bt 250mL | | | | |
| 134 | 150 | tbe | Silver Sulfadiazine crm tube 1% 15g | | | | |
| 135 | 20,000 | tab | Sodium Bicarbonate 650mg tab | | | | |
| 136 | 1,500 | vl | Sodium Chloride vl 2.5mEq/mL, 20mL | | | | |
| 137 | 700 | bt | Sodium Valproate 200 mg/5mL Syr 100mL | | | | |
| 138 | 500 | tab | Standard Senna Concentrate 187 mg tablet | | | | |
| 139 | 100 | amp | Terbutaline Sulf amp 500mcg/mL, 1mL (IV) | | | | |
| 140 | 200 | amp | Tetanus Toxoid amp 0.5mL (IM) (per Bid Bulletin No. BB-2022-010) | | | | |
| 141 | 20 | tbe | Tobramycin Eye Drp bt 0.3% 5mL | | | | |
| 142 | 60 | tbe | Tobramycin Eye Oint tbe 0.3% 3.5g | | | | |
| 143 | 11,000 | tab | Topiramate tab 50mg blister/foil pack | | | | |
| 144 | 1,500 | amp | Tranexamic Acid amp 100mg/mL, 5mL (IM, IV) | | | | |
| 145 | 2,500 | cap | Tranexamic Acid cap 500mg blister/foil pack | | | | |
| 146 | 5,000 | | | | | | |
| 147 | 100 | vl | Vaccine, Measles, Mumps, Rubella Live Atten 1dose vl+0.5mL dil (SC, IM) | | | | |
| 148 | 15,000 | tab | Valproic Acid + Sodium Valproate 500mg controlled release tablet | | | | |
| 149 | 1,200 | bt | VitB1B6B12 syr bt 100mg+5mg+50mcg, 120mL | | | | |
| 150 | 500 | bt | Zinc Sulfate drps bt 27.5mg/mL, 15mL | | | | |
| 151 | 1,575 | bt | Zinc Sulfate syr bt 55mg/5mL, 60mL | | | | |
| | 1332 1333 134 135 136 139 139 140 141 141 141 144 145 146 147 | 132 100 133 80 134 150 135 20,000 136 1,500 137 700 138 500 139 100 140 200 141 20 142 60 143 11,000 144 1,500 145 2,500 146 5,000 147 100 148 15,000 149 1,200 | No. Qty Unit 132 100 bt 133 80 bt 134 150 tbe 135 20,000 tab 136 1,500 vl 137 700 bt 138 500 tab 139 100 amp 140 200 amp 141 20 tbe 142 60 tbe 143 11,000 tab 144 1,500 amp 145 2,500 cap 146 5,000 cap 147 100 vl 148 15,000 tab 149 1,200 bt | Qty | 100 | No. | |

Additional Requirements :

Products to be bided should have passed the end-user's evaluation

NAME OF COMPANY ADDRESS Name of Project : VARIOUS PHARMACEUTICAL SUPPLIES $Total\ ABC = Php34,795,547.48$ Invitation to Bid No. IB 2023-089 A

TECHNICAL SPECIFICATIONS

| | PCMC's REQUIREMENT | | | BIDDER'S OFFER | | | |
|----------|--------------------|------|------------------|---|-------|--------------|--|
| Item No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER | |

SIGNATURE OVER PRINTED NAME

TELEPHONE / FAX NO.

PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City

Name of Project: VARIOUS PHARMACEUTICAL SUPPLIES
Total ABC = Php10,750,437.06
Invitation to Bid No. IB 2023-089 B (VAT EXEMPT)

| | PCMC'S REQUIREMENT BIDDER'S OFFER | | | | | | | |
|------|-----------------------------------|--------|--------|--|---|-------|--------------|--|
| Item | ı No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER | |
| В | 1 | 5,520 | bt/bag | 00.9% NaCl 1L (IV inf) | | | | |
| В | 2 | 3,840 | bt/bag | 00.9% NaCl 500mL (IV inf) | | | | |
| В | 3 | 17,000 | bt | 00.9% NaCl 50mL (IV inf) | | | | |
| В | 4 | 1,440 | bt/bag | 05% D in 0.9% NaCl 1L (IV inf) | | | | |
| В | 5 | 3,480 | bt/bag | 05% D in LR 1L (IV inf) | | | | |
| В | 6 | 1,200 | bt/bag | 05% D in LR 500mL (IV inf) | | | | |
| В | 7 | 800 | bt/bag | Acetated Ringer's Solution 1 L (IV) | | | | |
| В | 8 | 13,000 | tab | Aspirin tab 80mg blister/foil pack | | | | |
| В | 9 | 900 | bt/bag | Balanced Multiple Replacement soln 1L (IV inf) | | | | |
| В | 10 | 4,500 | bag | CAPD Solution 1.5% 2L with cap | | | | |
| В | 11 | 1,002 | bag | CAPD Solution 2.5% 2L with cap | | | | |
| В | 12 | 6,000 | tab | Captopril tab 25mg blister/foil pack | | | | |
| В | 13 | 400 | bt | Carbamazepine syr bt 100mg/5mL, 100mL | | | | |
| В | 14 | 20,000 | tab | Carbamazepine tab 200mg blister/foil pack | | | | |
| В | 15 | 5,000 | tab | Carvedilol 6.25mg tab blister/foil pack | | | | |
| В | 16 | 3,000 | tab | Ciclosporin tab 100mg blister/foil pack | | | | |
| В | 17 | 2,500 | tab | Clonazepam tab 2mg | | | | |
| В | 18 | 2,000 | tab | Desmopressin Acetate tab 100mcg | | | | |
| В | 19 | 3,000 | tab | Dexamethasone tab 4mg blister/foil pack | | | | |
| В | 20 | 500 | amp | Diazepam amp 5mg/mL, 2mL (IM,IV) | | | | |
| В | 21 | 200 | tab | Diazepam tab 5mg blister/foil pack | | | | |

Name of Project: VARIOUS PHARMACEUTICAL SUPPLIES Total ABC = Php10,750,437.06 Invitation to Bid No. IB 2023-089 B (VAT EXEMPT)

| | | | F | PCMC's REQUIREMENT | BIDDER'S OFFER | | | |
|------|-----|--------|--------|--|---|-------|--------------|--|
| Item | No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER | |
| В | 22 | 12,000 | tab | Enalapril Maleate tab 5mg blister/foil pack | | | | |
| В | 23 | 9,800 | amp | Epinephrine HCl amp 1mg/mL, 1mL (IV,IM,SC) | | | | |
| В | 24 | 500 | рс | Epoetin A (RH Erythropoeitin) pfs 4000 IU/0.4mL (IV,SC) | | | | |
| В | 25 | 2,010 | pc | Epoetin B (RH Erythropoeitin) pfs 2000 IU/0.3mL (IV,SC) | | | | |
| В | 26 | 2,000 | tab | Ethambutol HCl tab 400mg blister/foil pack | | | | |
| В | 27 | 80 | bt | Fluticasone Propionate 125mcg Inhaler 120 doses | | | | |
| В | 28 | 11,000 | tab | Furosemide tab 20mg blister/foil pack | | | | |
| В | 29 | 2,500 | tab | Furosemide tab 40mg blister/foil pack | | | | |
| В | 30 | 150 | amp | Glyceryl Trinitrate (Nitroglycerin) amp 1mg/mL, 10mL | | | | |
| В | 31 | 4,000 | cap | Hydroxyurea cap 500mg blister/foil pack | | | | |
| В | 32 | 80 | vl | Insulin Glargine 100IU/mL, 10mL vial | | | | |
| В | 33 | 300 | vl | Insulin Isophane Human (recomb DNA) vl 100IU/mL, 10mL (IM,SC) | | | | |
| В | 34 | 200 | vl | Insulin Regular Human (recomb DNA) vl 100IU/mL, 10mL (IM,IV,SC) | | | | |
| В | 35 | 1,200 | bt/bag | Lactated Ringer's soln 500mL (IV inf) | | | | |
| В | 36 | 15,000 | tab | Lamotrigin 50mg tablet | | | | |
| В | 37 | 240 | bt | Mannitol bt 20% 500mL (IV) sealed rubber cap | | | | |
| В | 38 | 10,000 | tab | Metformin HCl tab 500mg Film-coated blister/foil pack | | | | |
| В | 39 | 500 | tab | Methyldopa tab 250mg blister/foil pack | | | | |
| В | 40 | 1,500 | amp | Midazolam amp 5mg/mL, 1mL (IM,IV) | | | | |
| В | 41 | 1,000 | amp | Morphine Sulf amp 10mg/mL, 1mL (IM,IV) | | | | |
| В | 42 | 13,000 | tab | Mycophenolate Mofetil tab 500mg | | | | |
| В | 43 | 3,500 | tab | Mycophenolic Acid 360 mg tablet | | | | |

Name of Project: VARIOUS PHARMACEUTICAL SUPPLIES Total ABC = Php10,750,437.06 Invitation to Bid No. IB 2023-089 B (VAT EXEMPT)

| | | | F | PCMC's REQUIREMENT | BIDDER'S OFFER | | | |
|------|-----|--------|------|---|--|--|--------------|--|
| Item | No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) BRAND MANUFA | | MANUFACTURER | |
| В | 44 | 500 | cap | Nifedipine 10 mg capsule | V1 | | | |
| В | 45 | 2,800 | amp | Octreotide acetate 100mcg/mL | | | | |
| В | 46 | 8,000 | tab | Olanzapine tab 10mg blister/foil pack | | | | |
| В | 47 | 25,000 | tab | Oxcarbazepine 300mg tablet | | | | |
| В | 48 | 5,000 | tab | Oxcarbazepine 600mg tablet | | | | |
| В | 49 | 1,000 | bt | Oxcarbazepine 60mg/mL, 100mL suspension | | | | |
| В | 50 | 1,500 | tab | Potassium (as citrate) 10 mEq tablet | | | | |
| В | 51 | 6,500 | tab | Propranolol HCl tab 10mg blister/foil pack | | | | |
| В | 52 | 5,000 | tab | Risperidone tab 1mg blister/foil pack | | | | |
| В | 53 | 30 | vl | Rituximab 500mg inj. 50mL vial | | | | |
| В | 54 | 3,000 | tab | Sevelamer Carbonate 800mg tablet | | | | |
| В | 55 | 6,500 | tab | Sirolimus 0.5mg tab | | | | |
| В | 56 | 4,000 | tab | Spironolactone tab 25mg blister/foil pack | | | | |
| В | 57 | 20 | vl | Suxamethonium Chloride vl 20mg/mL, 10mL (IV) | | | | |
| В | 58 | 100 | vl | Tuberculin PPD powd 5TU w/ 2mL diluent | | | | |
| В | 59 | 1,200 | vl | Vancomycin HCl vl 500mg (IV) | | | | |
| В | 60 | 110 | vl | Vasopressin 20 IU/mL 1mL | | | | |

| Auditional Kequitements . | Additional | Requirements | : |
|---------------------------|------------|--------------|---|
|---------------------------|------------|--------------|---|

| NAME OF COMPANY | ADDRESS |
|-----------------------------|---------------------|
| | |
| | |
| SIGNATURE OVER PRINTED NAME | TELEPHONE / FAX NO. |

PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City

 $\label{eq:Name of Project: VARIOUS PHARMACEUTICAL SUPPLIES} \\ Total~ABC = Php262,559.50$

Invitation to Bid No. IB 2023-089 ${\rm C}$

Additional Requirements :

TECHNICAL SPECIFICATIONS

| | PCMC'S REQUIREMENT | | | | BIDDER'S OFFER | | | |
|----------|--------------------|-------|------|---|---|-------|--------------|--|
| Item No. | | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER | |
| C | 1 | 1,250 | vi | Hydrocortisone Sod Succ powd vl 100mg (IT,IM,IV) drypack | | | | |
| C | 2 | 500 | bt | Prednisone susp 10mg/5mL 60mL | | | | |
| C | 3 | 9,250 | tab | Prednisone tab 10mg blister/foil pack | | | | |
| C | 4 | 3,650 | tab | Prednisone tab 20mg blister/foil pack | | | | |

| NAME OF COMPANY | ADDRESS |
|-----------------|---------|
| | |

SIGNATURE OVER PRINTED NAME

Products to be bided should have passed the end-user's evaluation

TELEPHONE / FAX NO.

PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City

Name of Project: VARIOUS PHARMACEUTICAL SUPPLIES
Total ABC = Php66,700,371.75
Invitation to Bid No. IB 2023-089 D (VAT EXEMPT)

| | PCMC's REQUIREMENT BIDDER'S OFFER | | | | | | | | |
|------|-----------------------------------|-------|--------|---|---|-------|--------------|--|--|
| Item | No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER | | |
| D | 1 | 60 | vl | Bleomycin Sulf powd vl 15units (IM, IV, SC) | | | | | |
| D | 2 | 5,247 | vl | Calcium Folinate vl 50mg (IM,IV) | | | | | |
| D | 3 | 315 | vl | Carboplatin soln/powd vl 150mg (IV) | | | | | |
| D | 4 | 615 | vl | Carboplatin soln/powd vl 450mg (IV) | | | | | |
| D | 5 | 200 | vl | Cisplatin soln 1mg/mL vl 10mL (IV) | | | | | |
| D | 6 | 800 | vl | Cisplatin soln 1mg/mL vl 50mL (IV) | | | | | |
| D | 7 | 2,500 | vl | Cyclophosphamide powd vl 500mg (IV) | | | | | |
| D | 8 | 1,050 | vl | Cytarabine vl 1g, 10mL (IV inf) | | | | | |
| D | 9 | 730 | vl | Cytarabine vl 500mg, 5mL (IV, SC infusion) | | | | | |
| D | 10 | 4,916 | vl | Cytarabine vl 100mg (IT,IV) | | | | | |
| D | 11 | 140 | vl | Dacarbazine 200 mg Powder for Injection vial | | | | | |
| D | 12 | 388 | vl | Dactinomycin powd vl 500mcg | | | | | |
| D | 13 | 9,120 | tab | Dexamethasone tab 4mg blister/foil pack | | | | | |
| D | 14 | 860 | vl | Doxorubicin HCl powd/solution vl 10mg (IV) | | | | | |
| D | 15 | 1,560 | vl | Doxorubicin HCl powd/solution vl 50mg (IV) | | | | | |
| D | 16 | 2,021 | amp/vl | Etoposide amp/vl 20mg/mL, 5mL (IV) | | | | | |
| D | 17 | 8,868 | vl | Filgrastim (G-CSF) vl 300mcg/mL (IV,SC) | | | | | |
| D | 18 | 50 | vl | Fluorouracil vl 500mg IV | | | | | |
| D | 19 | 70 | vl | Idarubicin HCl vl powder 5mg (IV) | | | | | |
| D | 20 | 560 | vl | Ifosfamide vl 1g (IV infusion) | | | | | |
| D | 21 | 145 | vl | Ifosfamide vl 2g (IV infusion) | | | | | |

Name of Project: VARIOUS PHARMACEUTICAL SUPPLIES Total ABC = Php66,700,371.75 Invitation to Bid No. IB 2023-089 D (VAT EXEMPT)

TECHNICAL SPECIFICATIONS

| | PCMC's REQUIREMENT BIDDER'S OFFER | | | | | | |
|------|-----------------------------------|---------|------|--|---|-------|--------------|
| Item | No. | Qty | Unit | Item Description | ITEM DESCRIPTION (Specification, Packing, etc.) | BRAND | MANUFACTURER |
| D | 22 | 37,050 | tab | Imatinib 100mg tab | | | |
| D | 23 | 400 | vl | Irinotecan 40 mg/2mL(HCl) concentrate, vl (IV infusion) | | | |
| D | 24 | 1,560 | vl | L-Asparaginase lyoph powd vl 10,000IU (IV) | | | |
| D | 25 | 133,000 | tab | Mercaptopurine tab 50mg blister/foil pack | | | |
| D | 26 | 3,500 | amp | Mesna amp 400mg/4mL (IV) | | | |
| D | 27 | 3,675 | vl | Methotrexate Sod (Preservative Free) vl 100mg/mL, 10mL (IV,Intrathecal) | | | |
| D | 28 | 2,793 | vl | Methotrexate Sod (Preservative Free) vl 25mg/mL, 2mL (IM,IV,Intrathec) | | | |
| D | 29 | 113,590 | tab | Methotrexate Sod tab 2.5mg blister/foil pack | | | |
| D | 30 | 600 | tab | Morphine 10 mg Modified Release Tablet | | | |
| D | 31 | 130 | amp | Morphine Sulf amp 10mg/mL, 1mL (IM,IV) | | | |
| D | 32 | 11,567 | amp | Ondansetron amp 2mg/mL, 4mL (IV) | | | |
| D | 33 | 1,720 | tab | Ondansetron HCl tab 8mg blister/foil pack | | | |
| D | 34 | 30 | vl | Rituximab 100mg inj. 10mL vial | | | |
| D | 35 | 55 | vl | Rituximab 500mg inj. 50mL vial | | | |
| D | 36 | 4,750 | tab | Sirolimus 0.5mg tab | | | |
| D | 37 | 500 | tab | Sirolimus 1mg tab | | | |
| D | 38 | 596 | vl | Vinblastine Sulf powd vl 10mg (IV) | | | |
| D | 39 | 1,600 | vl | Vincristine Sulf vl 1mg/mL, 1mL (IV) | | | |
| D | 40 | 4,810 | vl | Vincristine Sulf vl 1mg/mL, 2mL (IV) | | | |

| Additional | Requirements | : |
|------------|--------------|---|
|------------|--------------|---|

Products to be bided should have passed the end-user's evaluation

| NAME OF COMPANY | ADDRESS |
|-----------------|---------|
| | |

SIGNATURE OVER PRINTED NAME

TELEPHONE / FAX NO.



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER

Bids and Awards Committee

Quezon Avenue, Quezon City 1100 website: www.pcmc.gov.ph email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION VIII

Checklist of Technical and Financial Documents

Supply and Delivery of Various Supplies for CY 2023

IB-2023-089 to 090

Checklist of Technical and Financial Documents

The Bidder shall submit the following <u>TECHNICAL COMPONENT ENVELOPE</u> (ARRANGED, <u>NUMBERED AND TABBED</u>) [Strictly NO using of staple wire and thick materials for tabs] as enumerated below:

I. TECHNICAL COMPONENT ENVELOPE

Class "A" Documents

Legal Documents

1. Valid PhilGEPS Registration Certificate (Platinum Membership) (all pages) in accordance with Section 8.5.2 of the IRR

Note: For the purpose of updating the Certificate of Registration and Membership, all Class "A" eligibility documents mentioned in this section supporting the veracity, authenticity and validity of the Certificate shall remain current and updated. The failure by the prospective bidder to update its Certificate with the current and updated Class "A" eligibility documents shall result in the automatic suspension of the validity of its Certificate until such time that all of the expired Class "A" eligibility documents has been updated (per GPPB Resolution No. 15-2021).

Technical Documents

- 2. Statement of the prospective bidder of all its ongoing government and private contracts, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid. (Use of Form No. DOBA-PCMC-SCF3b is required)
- 3. Statement of the bidder's Single Largest Completed Contract (SLCC) similar to the contract to be bid (*Refer to BDS Clause 5.3*), except under conditions provided for in Sections 23.4.1.3 and 23.4.4.4 of the 2016 Revised IRR of RA 9184, within two (2) years prior to bid opening (use of Form No. DOBA-PCMC-SCF3a is required).
- 4. Original copy of Bid Security (Refer to BDS Clause 14.1). If in the form of a Surety Bond, submit also a certification issued by the Insurance Commission or Original copy of Notarized Bid Securing Declaration
- 5. Duly accomplished and signed Production/ Delivery Schedule using the form as provided for in Section VI
- 6. Duly accomplished and signed Technical Specification using the form as provided for in Section VII
 - i. Signed Conforme on the Terms of Reference, (for Pharmaceutical Supplies)

7. Original duly signed Omnibus Sworn Statement (OSS); and if applicable, Original Notarized Secretary's Certificate in case of a corporation, partnership, or cooperative; or Original Special Power of Attorney of all members of the joint venture giving full power and authority to its officer to sign the OSS and do acts to represent the Bidder. (Use of the Form provided is required)

Financial Documents

8. The prospective bidder's computation of the Net Financial Contracting Capacity (NFCC) must be at least equal to the ABC to be bid (*Use of Form No. DOBA-PCMC-NFF4 is required*)

OR

a committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation, it must be at least equal to 10% of the ABC

Class "B" Documents

9. If applicable, a duly signed joint venture agreement (JVA) in case the joint venture is already in existence (*Use of Form No. DOBA-PCMC-JVF6 is required*).

OR

Duly notarized statements from all the potential joint venture partners stating that they will enter into and abide by the provisions of the JVA in the instance that the bid is successful

Other documentary requirements under RA NO. 9184 (as applicable)

- i. [For foreign bidders claiming by reason of their country's extension of reciprocal rights to Filipinos] Certification from the relevant government office of their country stating that Filipinos are allowed to participate in government procurement activities for the same item or product
- ii. Certification from the DTI if the Bidder claims preference as a Domestic Bidder or Domestic Entity

The Bidder shall submit the following <u>FINANCIAL COMPONENT ENVELOPE</u> (<u>ARRANGED</u>, <u>NUMBERED AND TABBED</u>) [Strictly NO using of staple wire and thick materials for tabs] as enumerated below:

II. FINANCIAL COMPONENT ENVELOPE

- 1. Duly accomplished and signed Financial Bid Form
- 2. Duly accomplished and signed **Price Schedule** using the form as provided

Note: Bidder shall include the PCMC-issued USB Flash Drive in the Financial Component Envelope (Original Folder) containing the FOLLOWING:

- a. Soft copy of their accomplished Price Schedule (in EXCEL format)
- b. **SCANNED copy** (in **PDF Format**) **of ALL** the required documents under Section VIII. Checklist of Technical and Financial Documents

| CONFORME: | | |
|---|--------------------------------|--|
| Authorized Signatory Signature over printed name | Contact No: | |
| Name of Company/Firm | | |
| Company's Official Email Address (where notices will be sent) | Company's Official Contact No. | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | · · · · · · · · · · · · · · · · · · · | | | | | | | | | | | | | | |
|-----|-------|---|-------|------|-----------------|------------|------------------|-------|--------------|----------------------|-------------------|---|--------------------------------------|---|--|---|
| | | PCMC REQ | | | | , | | | T | | IDDER'S C | | T | T | | |
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 1 | Acetazolamide tab 250mg blister/foil pack | 700 | tab | 14.93 | 10,451.00 | | | | | | | | | | |
| A | 2 | Acetylcysteine amp 100mg/mL 3mL (IMIV) | 3,500 | amp | 93.00 | 325,500.00 | | | | | | | | | | |
| A | 3 | Aciclovir Sod tab 800mg | 400 | tab | 38.38 | 15,352.00 | | | | | | | | | | |
| A | 4 | Aciclovir Sod vl 25mgmL, 10mL (IV inf) | 1,100 | vl | 215.04 | 236,544.00 | | | | | | | | | | |
| A | 5 | Adenosine vl 3mg/mL, 2mL (IV) | 30 | vl | 1,960.00 | 58,800.00 | | | | | | | | | | |
| A | 6 | Allopurinol tab 100mg blister/foil pack | 2,500 | tab | 4.75 | 11,875.00 | | | | | | | | | | |
| A | 7 | AlOH MgOH susp bt 225+200mg/5mL, 120mL | 512 | bt | 67.50 | 34,560.00 | | | | | | | | | | |
| A | 8 | Amiodarone HCl amp 50mg/mL, 3mL (IV) | 30 | amp | 268.00 | 8,040.00 | | | | | | | | | | |
| A | 9 | Amoxicillin Trihyd cap 500mg blister/foil pack | 4,500 | cap | 3.00 | 13,500.00 | | | | | | | | | | |
| A | 10 | Amoxicillin Trihyd susp bt 100mg/mL, 15mL | 300 | bt | 20.75 | 6,225.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | PCMC REQ | LIDEM | TENTE | | 1 | | | | D | IDDER'S C | AFFED | | | | |
|-----|-------|--|--------|-------|-----------------|------------|------------------|-------|--------------|----------------------|-----------|--------------------------------|--------------------------------------|---|--|---|
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 B | 10DER 5 C | TEK 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 11 | Amoxicillin Trihyd susp bt 250mg/5mL, 60mL | 280 | bt | 90.00 | 25,200.00 | | | | | | | | | | |
| A | 12 | Ampicillin Sod 500mg + Sulbactam 250mg vl (IM,IV) | 2,500 | vl | 84.82 | 212,050.00 | | | | | | | | | | |
| A | 13 | Ascorbic Acid drp bt 100mg/mL, 15mL | 456 | bt | 49.00 | 22,344.00 | | | | | | | | | | |
| A | 14 | Ascorbic Acid syr bt 100mg/5mL, 120mL | 3,500 | bt | 36.00 | 126,000.00 | | | | | | | | | | |
| A | 15 | Ascorbic Acid tab 500mg blister/foil pack | 60,000 | tab | 4.00 | 240,000.00 | | | | | | | | | | |
| A | 16 | Atropine Sulf amp 1mg/mL, 1mL (IM,IV) | 2,200 | amp | 20.56 | 45,232.00 | | | | | | | | | | |
| A | 17 | Azathioprine tab 50mg | 1,500 | tab | 38.42 | 57,630.00 | | | | | | | | | | |
| A | 18 | Azithromycin susp 200mg/5mL 15 mL | 200 | bt | 362.62 | 72,524.00 | | | | | | | | | | |
| A | 19 | Baclofen tab 10mg blister/foil pack | 6,000 | tab | 15.10 | 90,600.00 | | | | | | | | | | |
| A | 20 | Bisacodyl Pedia supp 5mg | 300 | supp | 45.00 | 13,500.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | PCMC REQ | LIDEM | IENIT | | | | | | D | IDDER'S C | EEED | | | | |
|-----|-------|--|--------|------------|-----------------|------------|------------------|-------|--------------|----------------------|------------|--------------------------------|--------------------------------------|---|--|---|
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 DEK 3 C | 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 21 | Bisacodyl tab 5mg blister/foil pack | 100 | tab | 10.00 | 1,000.00 | | | | | | | | | | |
| A | 22 | Blood Sugar Strip | 24,000 | рс | 10.00 | 240,000.00 | | | | | | | | | | |
| A | 23 | Budesonide+Formoterol 160/4.5mcg, 60doses | 90 | pc | 834.44 | 75,099.60 | | | | | | | | | | |
| A | 24 | Bupivacaine HCl in 8% Dextrose (heavy) amp 0.5%, 4mL, (spinal) | 100 | amp | 158.40 | 15,840.00 | | | | | | | | | | |
| A | 25 | Butamirate Citrate tab 50mg MR blister/foil pack | 300 | tab | 10.80 | 3,240.00 | | | | | | | | | | |
| A | 26 | Calcitriol cap 0.25mcg blister/foil pack | 6,000 | cap | 17.40 | 104,400.00 | | | | | | | | | | |
| A | 27 | Carbetocin amp/vl 100mcg (IV) | 100 | amp/ vl | 1,026.30 | 102,630.00 | | | | | | | | | | |
| A | 28 | Cefalexin Monohyd cap 500mg blister/foil pack | 600 | cap | 5.45 | 3,270.00 | | | | | | | | | | |
| A | 29 | Cefalexin Monohyd drp bt 100mg/mL, 10mL | 100 | bt | 19.68 | 1,968.00 | | | | | | | | | | |
| A | 30 | Cefalexin Monohyd syr/susp bt 250mg/5mL, 60mL | 150 | bt | 34.20 | 5,130.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | PCMC REQ | IIDEM | TENTE | | 1 | | | | D | IDDER'S C | VEEED | | | | |
|-----|-------|--|-------|-------|-----------------|------------|------------------|-------|--------------|----------------------|------------|--------------------------------|--------------------------------------|---|--|---|
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 9 | 10 DEK 5 C | 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 31 | Cefazolin Sod vl 1g (IM,IV) | 1,300 | vl | 27.88 | 36,244.00 | | | | | | | | | | |
| A | 32 | Ceftriaxone DiSod vl 1g + 10mL diluent (IV,IM) | 3,600 | vl | 120.00 | 432,000.00 | | | | | | | | | | |
| A | 33 | Cefuroxime susp bt 125mg/5mL, 70mL | 200 | bt | 210.00 | 42,000.00 | | | | | | | | | | |
| A | 34 | Cefuroxime susp bt 250mg/5mL, 50mL | 600 | bt | 130.00 | 78,000.00 | | | | | | | | | | |
| A | 35 | Celecoxib cap 100mg blister/foil pack | 1,000 | cap | 2.90 | 2,900.00 | | | | | | | | | | |
| A | 36 | Celecoxib cap 200mg blister/foil pack | 2,000 | cap | 2.90 | 5,800.00 | | | | | | | | | | |
| A | 37 | Cetirizine Dihydrochloride drp bt 2.5mg/mL 10mL | 150 | bt | 74.00 | 11,100.00 | | | | | | | | | | |
| A | 38 | Ciprofloxacin HCl tab 500mg blister/foil pack | 8,000 | tab | 8.80 | 70,400.00 | | | | | | | | | | |
| A | 39 | Ciprofloxacin Lactate vl 2mg/mL, 100mL (IV inf), sealed rubber cap | 3,020 | vl | 265.19 | 800,873.80 | | | | | | | | | | |
| A | 40 | Clarithromycin susp bt 250mg/5mL gran 50mL | 150 | bt | 360.00 | 54,000.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | DCMC DEO | IIDEM | TENTE | | 1 | | | | D | IDDEDIC C | AFFED | | | | |
|-----|-------|--|--------|-------------|-----------------|--------------|------------------|-------|--------------|----------------------|-----------|--------------------------------|--------------------------------------|---|--|---|
| - | | PCMC REQ | 2 | 3 | 4 | 5 | 6 | 7 | 8 | <u>в</u> | IDDER'S C | TEK 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 41 | Clindamycin PO4 amp 150mg/mL 4mL (IM,IV) | 800 | amp | 235.00 | 188,000.00 | | | | | | | | | | |
| A | 42 | Clotrimazole 1% cream 10g | 100 | tbe | 170.50 | 17,050.00 | | | | | | | | | | |
| A | 43 | Cloxacillin Sod syr/susp bt 250mg/5mL, 60mL | 200 | bt | 42.00 | 8,400.00 | | | | | | | | | | |
| A | 44 | Cotrimoxazole susp bt 200mg + 40mg/5mL, 60mL / 70mL | 2,000 | bt | 38.28 | 76,560.00 | | | | | | | | | | |
| A | 45 | Cotrimoxazole susp bt 400mg + 80mg/5mL, 60mL | 2,800 | bt | 31.20 | 87,360.00 | | | | | | | | | | |
| A | 46 | Cotrimoxazole tab/cap 800mg + 160mg blister/foil pack | 16,000 | cap/ tab | 3.90 | 62,400.00 | | | | | | | | | | |
| A | | Deferasirox 250mg dispersible tablet | 2,300 | tab | 493.30 | 1,134,590.00 | | | | | | | | | | |
| A | 48 | Deferasirox tab 180mg | 1,500 | tab | 548.00 | 822,000.00 | | | | | | | | | | |
| A | 49 | Deferasirox tab 90mg | 1,500 | tab | 274.00 | 411,000.00 | | | | | | | | | | |
| A | 50 | Deferiprone tab 500mg | 5,000 | tab | 125.00 | 625,000.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | PCMC REQ | HDEM | IENIT | | | | | | D | IDDER'S C | EEED | | | | |
|----------|-------|--|-------|-------|-----------------|--------------|------------------|-------|--------------|----------------------|------------|--------------------------------|--------------------------------------|---|--|---|
| \vdash | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 9 | 10 DEK 5 C | TEK 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 51 | Digoxin amp 250mcg/mL, 2mL (IM,IV) | 20 | amp | 310.00 | 6,200.00 | | | | | | | | | | |
| A | 52 | Digoxin tab 250mcg | 5,000 | tab | 4.04 | 20,200.00 | | | | | | | | | | |
| A | 53 | Diphenhydramine HCl AF syr bt 12.5mg/5mL, 60mL | 300 | bt | 21.48 | 6,444.00 | | | | | | | | | | |
| A | 54 | Diphenhydramine HCl cap 25mg | 1,000 | cap | 1.98 | 1,980.00 | | | | | | | | | | |
| A | 55 | Diphenhydramine HCl cap 50mg blister/foil pack | 1,500 | cap | 3.50 | 5,250.00 | | | | | | | | | | |
| A | 56 | Domperidone susp bt 1mg/mL, 60mL | 240 | bt | 60.00 | 14,400.00 | | | | | | | | | | |
| A | | Domperidone tab 10mg blister/foil pack | 2,500 | tab | 2.11 | 5,275.00 | | | | | | | | | | |
| A | 58 | Erythromycin Stearate tab 500mg blister/foil pack | 200 | tab | 7.02 | 1,404.00 | | | | | | | | | | |
| A | 59 | Esmolol HCl vl 100mg/mL, 10mL | 40 | vl | 475.00 | 19,000.00 | | | | | | | | | | |
| A | 60 | Factor VIII Conc lyoph powd vl + diluent (IV) 100 IU/mL | 1,050 | vl | 8,350.00 | 8,767,500.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | PCMC REQ | | | | , | | | T | | IDDER'S C | | | 1 | | |
|-----|-------|---|--------|-------------|-----------------|-----------|------------------|-------|--------------|----------------------|-------------------|---|--------------------------------------|---|--|---|
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 61 | Famotidine tab 20mg | 1,000 | tab | 23.01 | 23,010.00 | | | | | | | | | | |
| A | 62 | Ferrous Salt soln bt drp 15mg/0.6mL 15mL | 280 | bt | 23.84 | 6,675.20 | | | | | | | | | | |
| A | 63 | Ferrous Salt+Folic Acid tab/cap/film coated tab blister/foil pack | 20,000 | cap/t ab | 3.00 | 60,000.00 | | | | | | | | | | |
| A | 64 | Fluconazole cap 50mg blister/foil pack | 1,000 | cap | 56.00 | 56,000.00 | | | | | | | | | | |
| A | 65 | Fluocinolone acetonide 250mcg + Neomycin Sulfate 3.5mg + Polymyxin B Sulfate Otic Drops | 50 | bt | 229.90 | 11,495.00 | | | | | | | | | | |
| A | 66 | Folic Acid 5mg blister/foil pack | 2,000 | cap/t ab | 2.95 | 5,900.00 | | | | | | | | | | |
| A | 67 | Folic acid drp 2.5mg/mL | 250 | bt | 130.00 | 32,500.00 | | | | | | | | | | |
| A | 68 | Folic acid syr 5mg/mL | 250 | bt | 206.00 | 51,500.00 | | | | | | | | | | |
| A | 69 | Glycerol Infant supp 1.9g | 360 | supp | 3.85 | 1,386.00 | | | | | | | | | | |
| A | 70 | Hepatitis A Vaccine 80U/0.5mL | 20 | рс | 1,270.00 | 25,400.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | PCMC REQ | HDEM | IENIT | | | | | | D | IDDER'S C | EEED | | | | |
|-----|-------|--|-------|-------|-----------------|--------------|------------------|-------|--------------|----------------------|-----------|--------------------------------|--------------------------------------|---|--|---|
| - | | PCMC REQU | 2 | IEN I | 4 | 5 | 6 | 7 | 8 | 9 9 | 10DEK'S C | PFFEK 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 71 | Hydrocortisone Sod Succ powd vl 100mg (IT,IM,IV) drypack | 1,440 | vl | 104.00 | 149,760.00 | | | | | | | | | | |
| A | 72 | Hydrocortisone Sod Succ vl 250mg/2mL, w/ 2mL diluent (IV/II) | 960 | vl | 255.00 | 244,800.00 | | | | | | | | | | |
| A | 73 | Hydrocortisone Valerate 1% cream 10g | 70 | tbe | 139.15 | 9,740.50 | | | | | | | | | | |
| A | 74 | Hydrogen Peroxide bt 3% 120mL | 276 | bt | 17.40 | 4,802.40 | | | | | | | | | | |
| A | 75 | Hydroxychloroquine 200 mg tablet | 700 | tab | 38.15 | 26,705.00 | | | | | | | | | | |
| A | 76 | Ibuprofen tab 200mg blister/foil pack | 1,000 | tab | 1.39 | 1,390.00 | | | | | | | | | | |
| A | 77 | Ibuprofen tab 400mg blister/foil pack | 1,000 | tab | 0.84 | 840.00 | | | | | | | | | | |
| A | 78 | Immunoglobulin, Hepatitis B H vl 100IU 0.5mL | 100 | vl | 2,150.00 | 215,000.00 | | | | | | | | | | |
| A | 79 | Immunoglobulin, NH IGIV vl 2500mg (2.5g) | 1,100 | vl | 6,922.00 | 7,614,200.00 | | | | | | | | | | |
| A | 80 | Iodixanol 652mg/mL (320mg iodine), 50mL | 300 | vl | 2,533.32 | 759,996.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | - | | | | | | | | | | | | | | |
|-----|-------|--|-------|------|-----------------|--------------|------------------|-------|--------------|----------------------|-------------------|---|--------------------------------------|---|--|---|
| | | PCMC REQ | | | | | | | 1 | | IDDER'S C | | | | T | |
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 81 | Iohexol vl 300mg iodine/mL, 50mL | 120 | vl | 1,035.01 | 124,201.20 | | | | | | | | | | |
| A | 82 | Iopromide 300 mg/mL equiv. to 623 mg iodine, 50 mL Vial | 500 | vial | 889.35 | 444,675.00 | | | | | | | | | | |
| A | 83 | Ioversol 636 mg/mL (300mg/mL iodine) 50mL | 430 | vl | 1,200.00 | 516,000.00 | | | | | | | | | | |
| A | 84 | Ioversol 741 mg/mL (350mg/mL iodine) 50mL | 100 | vl | 1,573.00 | 157,300.00 | | | | | | | | | | |
| A | | Iron sucrose 20 mg/mL, 5 mL ampule | 100 | amp | 122.54 | 12,254.00 | | | | | | | | | | |
| A | 86 | Lagundi syr bt 300mg/5mL, 60mL | 200 | bt | 54.00 | 10,800.00 | | | | | | | | | | |
| A | | Lagundi tab 300mg blister/foil pack | 500 | tab | 2.70 | 1,350.00 | | | | | | | | | | |
| A | | Lansoprazole cap 30mg FDT blister/foil pack | 1,500 | cap | 7.70 | 11,550.00 | | | | | | | | | | |
| A | 89 | Levetiracetam 100mg/mL Oral Solution, 300mL | 950 | bt | 1,086.25 | 1,031,937.50 | | | | | | | | | | |
| A | 90 | Levetiracetam 100mg/mL, 5mL vl concentrate solution of IV | 3,400 | vl | 671.13 | 2,281,842.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | PCMC REQ | LIDEM | TENTE | | 1 | | | | D | IDDER'S C | AFFED | | | | |
|-----|-------|--|------------|-------|-----------------|------------|------------------|-------|--------------|----------------------|------------|--------------------------------|--------------------------------------|---|--|---|
| | | 1 PCMC REQ | OIKEM 2 | 3 | 4 | 5 | 6 | 7 | 8 | <u>в</u> | 10 DEK'S C | TEK 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 91 | Levetiracetam 250 mg FCT | 11,000 | tab | 11.19 | 123,090.00 | | | | | | | | | | |
| A | 92 | Levofloxacin tab 500 mg | 500 | tab | 5.40 | 2,700.00 | | | | | | | | | | |
| A | 93 | Levothyroxin tab 100 mcg | 2,000 | tab | 6.38 | 12,760.00 | | | | | | | | | | |
| A | 94 | Levothyroxin tab 50 mcg | 2,000 | tab | 3.25 | 6,500.00 | | | | | | | | | | |
| A | 95 | Lubricating Jelly scht 5g | 2,500 | pc | 4.95 | 12,375.00 | | | | | | | | | | |
| A | 96 | Lubricating Jelly tbe 82g (150g) | 300 | tbe | 159.50 | 47,850.00 | | | | | | | | | | |
| A | 97 | Mebendazole susp bt 100mg/5mL, 60mL | 50 | bt | 27.50 | 1,375.00 | | | | | | | | | | |
| A | 98 | Meropenem Trihydrate vl 1g (IV) | 2,000 | vl | 322.00 | 644,000.00 | | | | | | | | | | |
| A | 99 | Mesalazine 500mg tab EC | 4,200 | tab | 60.98 | 256,116.00 | | | | | | | | | | |
| A | 100 | Methimazole 5mg tab | 4,500 | tab | 4.46 | 20,070.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | PCMC REQ | IIDEM | TENTE | | 1 | | | | D | IDDER'S C | AFFED | | | | |
|-----|-------|---|-------|-------|-----------------|------------|------------------|-------|--------------|----------|-------------------|--------------------------------|--------------------------------------|---|--|---|
| | | 1 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | <u>в</u> | 10DER'S C | FFEK 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 101 | Methylergometrine Maleate amp 200mcg/mL, 1mL (IM,IV) | 100 | amp | 64.00 | 6,400.00 | | | | | | | | | | |
| A | 102 | Methylprednisolone Sod Succ vl 500mg/7.7mL+diluent (IV) | 500 | vl | 1,155.00 | 577,500.00 | | | | | | | | | | |
| A | 103 | Metronidazole tab 500mg blister/foil pack | 1,000 | tab | 5.00 | 5,000.00 | | | | | | | | | | |
| A | 104 | Metronidazole vl 5mg/mL, 100mL (IV inf), sealed rubber cap | 1,000 | vl | 53.95 | 53,950.00 | | | | | | | | | | |
| A | 105 | Mineral Oil 1L | 10 | bt | 242.00 | 2,420.00 | | | | | | | | | | |
| A | 106 | Montelukast Sodium chewable tab 5mg blister/foil pack | 1,400 | tab | 3.20 | 4,480.00 | | | | | | | | | | |
| A | 107 | Multivitamins drp bt 15mL | 424 | bt | 51.62 | 21,886.88 | | | | | | | | | | |
| A | 108 | Mupirocin oint tube 2% 15g | 200 | tbe | 160.00 | 32,000.00 | | | | | | | | | | |
| A | 109 | Nalbuphine HCl amp 10mg/mL, 1 mL preservative free (IM, IV, SC) | 1,000 | amp | 58.14 | 58,140.00 | | | | | | | | | | |
| A | 110 | Nitrofurantoin macrocrystals cap 100mg blister/foil pack | 800 | cap | 10.00 | 8,000.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

INVITATION TO BID NO. ${\bf IB extbf{-}2023 extbf{-}089}$ ${\bf A}$

| | | - | | | | | | | | | | | | | | |
|-----|-------|---|--------|------|-----------------|------------|------------------|-------|--------------|----------------------|-----------|---|--------------------------------------|---|--|---|
| | | PCMC REQ | | | | | | | 1 | | IDDER'S C | | | 1 | 1 | |
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 111 | Oxymetazoline HCl nasal drp 0.025% 10mL | 20 | bt | 216.00 | 4,320.00 | | | | | | | | | | |
| A | 112 | Oxymetazoline HCl nasal spray 0.05% 15mL | 20 | bt | 234.49 | 4,689.80 | | | | | | | | | | |
| A | 113 | Paracetamol 10mg/mL, 100mL Soln for infusion (IV) | 1,200 | vl | 190.00 | 228,000.00 | | | | | | | | | | |
| A | 114 | Paracetamol Alcohol Free drp bt 100mg/mL, 15mL | 712 | bt | 18.60 | 13,243.20 | | | | | | | | | | |
| A | 115 | Paracetamol Alcohol Free syr/susp bt 250mg/5mL, 60mL | 3,560 | bt | 50.00 | 178,000.00 | | | | | | | | | | |
| A | 116 | Penicillin G Sod vl 1,000,000U (IM,IV) | 600 | vl | 16.88 | 10,128.00 | | | | | | | | | | |
| A | 117 | Petroleum jelly 25g | 120 | jar | 34.65 | 4,158.00 | | | | | | | | | | |
| A | 118 | Phenobarbital Sod tab 30mg (gr1/2) | 30,000 | tab | 3.52 | 105,600.00 | | | | | | | | | | |
| A | 119 | Phenytoin Sod amp 50mg/mL, 5mL (IV) | 300 | amp | 438.90 | 131,670.00 | | | | | | | | | | |
| A | 120 | Phytomenadione colloidal soln amp 10mg/mL, 1mL (IV,IM,SC) | 6,500 | amp | 20.13 | 130,845.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

| | | PCMC REQ | LIDEM | ENT | | 1 | | | | D | IDDER'S C | AFFED | | | | |
|-----|-------|--|--------|--------------|-----------------|------------|------------------|-------|--------------|----------------------|-----------|--------------------------------|--------------------------------------|---|--|---|
| - | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 9 | 10DER 5 C | TEK 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | | Pneumococcal Polyvalent Vaccine 25mcg/0.5mL sol for inj, 0.5mL pfs/vial (IM, SC) | 100 | pfs/v ial | 1,656.00 | 165,600.00 | | | | | | | | | | |
| A | 122 | Povidone Iodine Antiseptic 10% 120mL spray bottle | 960 | bt | 32.45 | 31,152.00 | | | | | | | | | | |
| A | | Povidone Iodine Oral Soln 1% bt 60mL | 50 | bt | 98.14 | 4,907.00 | | | | | | | | | | |
| A | 124 | Prednisone susp 10mg/5mL 60mL | 1,500 | bt | 91.00 | 136,500.00 | | | | | | | | | | |
| A | 125 | Prednisone tab 10mg blister/foil pack | 3,000 | tab | 1.27 | 3,810.00 | | | | | | | | | | |
| A | 126 | Prednisone tab 20mg blister/foil pack | 11,000 | tab | 4.88 | 53,680.00 | | | | | | | | | | |
| A | | Prednisone tab 5mg blister/foil pack | 1,500 | tab | 1.42 | 2,130.00 | | | | | | | | | | |
| A | 128 | Proparacaine 0.5% eye drops solution, 5 mL bottle | 10 | bt | 120.00 | 1,200.00 | | | | | | | | | | |
| A | 129 | Ranitidine HCl tab 150mg blister/foil pack | 600 | tab | 3.30 | 1,980.00 | | | | | | | | | | |
| A | 130 | Salbutamol Inhaler 100mcg x 200 dose | 200 | рс | 89.00 | 17,800.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

INVITATION TO BID NO. ${\bf IB extbf{-}2023 extbf{-}089}$ ${\bf A}$

| | | PCMC REQ | IIDEM | TAIT | | 1 | | | | D | IDDER'S C | AFFED | | | | |
|-----|-------|---|--------|------|-----------------|------------|------------------|-------|--------------|----------------------|-----------|--------------------------------|--------------------------------------|---|--|---|
| | | PCMC REQ | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 9 | 10DER'S C | FFEK 11 | 12 | 13 | 14 | 15 |
| ITE | M NO. | ITEM DESCRIPTION | | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT | COST OF LOCAL LABOR, RAW | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 131 | Salbutamol Sulf nebul soln 1mg/mL, 2.5mL (monodose) | 11,000 | neb | 10.00 | 110,000.00 | | | | | | | | | | |
| A | 132 | Salbutamol Sulf syr bt 2mg/5mL, 60mL | 100 | bt | 46.20 | 4,620.00 | | | | | | | | | | |
| A | 133 | Sevoflurane inhalation bt 250mL | 80 | bt | 8,500.00 | 680,000.00 | | | | | | | | | | |
| A | 134 | Silver Sulfadiazine crm tube 1% 15g | 150 | tbe | 62.08 | 9,312.00 | | | | | | | | | | |
| A | 135 | Sodium Bicarbonate 650mg tab | 20,000 | tab | 1.80 | 36,000.00 | | | | | | | | | | |
| A | 136 | Sodium Chloride vl 2.5mEq/mL, 20mL | 1,500 | vl | 19.50 | 29,250.00 | | | | | | | | | | |
| A | 137 | Sodium Valproate 200 mg/5mL Syr 100mL | 700 | bt | 193.60 | 135,520.00 | | | | | | | | | | |
| A | 138 | Standard Senna Concentrate 187 mg tablet | 500 | tab | 16.22 | 8,110.00 | | | | | | | | | | |
| A | 139 | Terbutaline Sulf amp 500mcg/mL, 1mL (IV) | 100 | amp | 48.28 | 4,828.00 | | | | | | | | | | |
| A | 140 | Tetanus Toxoid amp 0.5mL (IM) (per Bid Bulletin No. BB- 2022-010) | 200 | amp | 38.84 | 7,768.00 | | | | | | | | | | |

PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER

NAME OF BIDDER:

NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023

INVITATION TO BID NO. ${\bf IB extbf{-}2023 extbf{-}089}$ ${\bf A}$

| \vdash | | 2010 | | (T) *** | | | | | | _ | IDDEE: | EEED | | | | |
|----------|-------|---|--------|---------|-----------------|------------|--------------------|--------------|----------------|---------------------------|----------------|--|--------------------------------------|---|--|--|
| - | | PCMC REQ | | | | - | | - | | | IDDER'S C | | 10 | 12 | 14 | 15 |
| ITE | M NO. | 1 ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | 6 ITEM DESCRIPTION | 7 BRAND | 8 MANUFACTURER | 9 COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A | 141 | Tobramycin Eye Drp bt 0.3% 5mL | 20 | tbe | 350.00 | 7,000.00 | | | | | | | | | | |
| A | 142 | Tobramycin Eye Oint tbe 0.3% 3.5g | 60 | tbe | 192.39 | 11,543.40 | | | | | | | | | | |
| A | 143 | Topiramate tab 50mg blister/foil pack | 11,000 | tab | 8.75 | 96,250.00 | | | | | | | | | | |
| A | 144 | Tranexamic Acid amp 100mg/mL, 5mL (IM, IV) | 1,500 | amp | 25.50 | 38,250.00 | | | | | | | | | | |
| A | 145 | Tranexamic Acid cap 500mg blister/foil pack | 2,500 | cap | 6.60 | 16,500.00 | | | | | | | | | | |
| A | 146 | Ursodeoxycholic Acid cap 250mg blister/foil pack | 5,000 | cap | 33.81 | 169,050.00 | | | | | | | | | | |
| A | 147 | Vaccine, Measles,Mumps,Rubella Live Atten 1dose vl+0.5mL dil (SC,IM) | 100 | vl | 1,190.00 | 119,000.00 | | | | | | | | | | |
| A | | Valproic Acid + Sodium Valproate 500mg controlled release tablet | 15,000 | tab | 7.45 | 111,750.00 | | | | | | | | | | |
| A | 149 | VitB1B6B12 syr bt 100mg+5mg+50mcg, 120mL | 1,200 | bt | 99.00 | 118,800.00 | | | | | | | | | | |
| A | 150 | Zinc Sulfate drps bt 27.5mg/mL, 15mL | 500 | bt | 32.00 | 16,000.00 | | | | | | | | | | |

| | | | | | | PR | ICE SC | HEDU | L E | | | | | | |
|----------|---|--------------|---------------|-------------------|---------------------|------------------------------------|----------------------------|--------------------------|----------------------|-------------------|---|--------------------------------------|---|--|---|
| PROCU | RING ENTITY: PHILIPPINE C | HILD | REN | 'S MEDI | CAL CEN | <u>TER</u> | | | | | | NAME OF BI | DDER: | | |
| NAME | OF PROJECT : PHARMACEUTICA | L SUPI | PLIES | CY 2023 | | | | | INVITATION | TO BID NO. $f I$ | B-2023-089 A | | | | |
| | PCMC REQ | UIREM | ENT | | | | | | В | IDDER'S C | FFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM N | D. ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| A 15 | A 151 Zinc Sulfate syr bt 55mg/5mL, 60mL 1,575 bt 35.00 55,125.00 COMPONENT SERVICES AWARDED 12 | | | | | | | | | | | | | | |
| | TIONAL REQUIREMENTS: | | | | 34) 33(34) 40 | | | | тот | AL = | | | | | |
| | orme on the attached Terms of Refere | | | | | | | | | | TERMS OF PAYME | NT (For discount | s being offered, if the | ere's any. Otherwise. | . state "NONE") : |
| | and Medicines to be delivered should have exp | | | e (1) year and lo | nger or as expresse | d/ required by Pharmacy | | | | | | (| , | | , |
| | ice of the bided item(s) shall be valid until Dec | ember 31, | 2023 | | | | | | | | | | | | |
| | red delivery, staggered payment | | | | | | | | | | | | | | |
| | antities specified are estimated requirements of called for on this biddin | luring the p | eriod and | may be decreas | ed depending upon | the actual need of PCMC. It is und | lerstood therefore that PC | MC is not bound to order | / purchase all the | items / | | | | | |
| ➤ The su | pplier should submit Materials Safety Data Sh | eet upon de | elivery, if a | applicable | | | | | | | NAM | ME AND SIGNAT | URE OF AUTHORIZ | ZED REPRESENTAT | TIVE |
| ➤ PCMC | has the right to reject any or all bids without of | offering any | reason, v | waive any require | ed formality and aw | ard the contract to any bidder who | ose proposals as evaluated | by PCMC is the most adv | vantageous to the | | BAC & END-USER'S | SIGNATURE: | | | |

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 4 5 7 9 10 11 12 13 14 15 1 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL LOCAL LABOR, OTHER TAXES DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER FINAL NO. PRICE EXW ITEM DESCRIPTION QTY UNIT TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW MATERIAL. ITEM IF DESTINATION OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 bt/ 1 00.9% NaCl 1L (IV inf) 5,520 34.50 190,440.00 bag bt/ 2 00.9% NaCl 500mL (IV inf) 3,840 88,128.00 22.95 bag 448,800.00 3 00.9% NaCl 50mL (IV inf) 17,000 bt 26.40 bt/ 4 05% D in 0.9% NaCl 1L (IV inf) 1,440 34.00 48,960.00 bag bt/ 121,800.00 5 05% D in LR 1L (IV inf) 3,480 35.00 bag bt/ 6 05% D in LR 500mL (IV inf) 1,200 42,000.00 35.00 bag Acetated Ringer's Solution 1 L bt/ 150,000.00 В 800 187.50 (IV) bag Aspirin tab 80mg blister/foil 13,000 0.67 8,710.00 tab pack Balanced Multiple Replacement bt/ 32,292.00 35.88 soln 1L (IV inf) bag CAPD Solution 1.5% 2L with 10 4,500 743,310.00 bag 165.18

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 3 4 5 7 9 10 11 12 13 14 15 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL LOCAL LABOR, OTHER TAXES DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER **FINAL** NO. PRICE EXW ITEM DESCRIPTION QTY UNIT TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW MATERIAL. ITEM IF DESTINATION OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 CAPD Solution 2.5% 2L with 1,002 bag 165,510.36 165.18 Captopril tab 25mg blister/foil 12 6,000 tab 18,000.00 3.00 pack Carbamazepine syr bt 13 120,000.00 400 bt 300.00 100mg/5mL, 100mL Carbamazepine tab 200mg 45,000.00 20,000 tab 2.25 blister/foil pack Carvedilol 6.25mg tab 15 5,700.00 В 5,000 tab 1.14 blister/foil pack Ciclosporin tab 100mg 364,290.00 3,000 tab 121.43 blister/foil pack 17 Clonazepam tab 2mg 2,500 tab 3.54 8,850.00 Desmopressin Acetate tab 2,000 50.60 101,200.00 tab 100mcg Dexamethasone tab 4mg 75,000.00 3,000 tab 25.00 blister/foil pack Diazepam amp 5mg/mL, 2mL 20 500 97.69 48,845.00 amp (IM,IV)

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 3 4 5 7 9 10 11 12 13 14 15 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL LOCAL LABOR, OTHER TAXES DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER **FINAL** NO. PRICE EXW ITEM DESCRIPTION QTY UNIT TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW MATERIAL. ITEM IF DESTINATION OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 Diazepam tab 5mg blister/foil 1,988.00 200 9.94 tab pack Enalapril Maleate tab 5mg 22 12,000 99,720.00 tab 8.31 blister/foil pack Epinephrine HCl amp 23 784,000.00 9,800 amp 80.00 1mg/mL, 1mL (IV,IM,SC) Epoetin A (RH Erythropoeitin) 500 380.00 190,000.00 pc pfs 4000 IU/0.4mL (IV,SC) Epoetin B (RH Erythropoeitin) 25 829,125.00 2,010 412.50 pc pfs 2000 IU/0.3mL (IV,SC) Ethambutol HCl tab 400mg 6,100.00 2,000 tab 3.05 blister/foil pack Fluticasone Propionate 125mcg В 27 80 bt 211.97 16,957.60 Inhaler 120 doses Furosemide tab 20mg 11,000 16,500.00 tab 1.50 blister/foil pack Furosemide tab 40mg 29 6,250.00 2,500 tab 2.50 blister/foil pack Glyceryl Trinitrate 30 (Nitroglycerin) amp 1mg/mL, 65,520.00 150 436.80 amp 10mL

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 3 4 5 9 10 11 12 13 14 15 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL LOCAL LABOR, OTHER TAXES DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER FINAL NO. PRICE EXW ITEM DESCRIPTION QTY UNIT TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW DESTINATION MATERIAL. ITEM IF OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 Hydroxyurea cap 500mg 69,600.00 4,000 17.40 cap blister/foil pack Insulin Glargine 100IU/mL, 32 80 1,247.00 99,760.00 vl10mL vial Insulin Isophane Human 33 (recomb DNA) vl 100IU/mL, 30,420.00 300 vl101.40 10mL (IM,SC) Insulin Regular Human 34 (recomb DNA) vl 100IU/mL, 200 vl106.40 21,280.00 10mL (IM,IV,SC) Lactated Ringer's soln 500mL bt/ba 35 41,400.00 В 1,200 34.50 (IV inf) 36 Lamotrigin 50mg tablet 99,000.00 15,000 tab 6.60 Mannitol bt 20% 500mL (IV) 37 В 240 bt 76.00 18,240.00 sealed rubber cap Metformin HCl tab 500mg Film-10,000 tab 0.90 9,000.00 coated blister/foil pack Methyldopa tab 250mg 4,500.00 500 tab 9.00 blister/foil pack Midazolam amp 5mg/mL, 1mL 40 1,500 134,910.00 89.94 amp (IM,IV)

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 3 4 5 7 9 10 11 12 13 14 15 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL OTHER TAXES LOCAL LABOR, DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER **FINAL** NO. PRICE EXW ITEM DESCRIPTION QTY UNIT TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW MATERIAL. ITEM IF DESTINATION OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 Morphine Sulf amp 10mg/mL, 78,500.00 1,000 78.50 amp 1mL (IM,IV) Mycophenolate Mofetil tab 42 13,000 tab 592,020.00 45.54 500mg Mycophenolic Acid 360 mg 205,485.00 43 3,500 tab 58.71 tablet 2,750.00 44 Nifedipine 10 mg capsule 500 cap 5.50 45 Octreotide acetate 100mcg/mL 371.25 1,039,500.00 2,800 amp Olanzapine tab 10mg 48,000.00 8,000 tab 6.00 blister/foil pack 47 Oxcarbazepine 300mg tablet 25,000 tab 10.82 270,500.00 48 Oxcarbazepine 600mg tablet 5,000 121,150.00 tab 24.23 Oxcarbazepine 60mg/mL, 523,000.00 1.000 bt 523.00 100mL suspension Potassium (as citrate) 10 mEq 50 1,500 10,470.00 tab 6.98 tablet

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 3 4 5 9 10 11 12 13 14 15 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL LOCAL LABOR, OTHER TAXES DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER **FINAL** NO. UNIT PRICE EXW ITEM DESCRIPTION QTY TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW MATERIAL. ITEM IF DESTINATION OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 Propranolol HCl tab 10mg 41,275.00 6,500 tab 6.35 blister/foil pack Risperidone tab 1mg 52 5,000 37,250.00 tab 7.45 blister/foil pack B 53 Rituximab 500mg inj. 50mL vial vl33,371.37 1,001,141.10 Sevelamer Carbonate 800mg 3,000 tab 34.63 103,890.00 tablet 55 Sirolimus 0.5mg tab 845,000.00 6,500 tab 130.00 Spironolactone tab 25mg 52,000.00 4,000 tab 13.00 blister/foil pack Suxamethonium Chloride vl 57 В 20 vl300.00 6,000.00 20mg/mL, 10mL (IV) Tuberculin PPD powd 5TU w/ vl635.00 63,500.00 2mL diluent 141,000.00 59 Vancomycin HCl vl 500mg (IV) 1,200 vl117.50 60 Vasopressin 20 IU/mL 1mL 1,790.00 196,900.00 110 vlTOTAL = 10,750,437.06

| | | | | | | PR | ICE SC | HEDU | L.E | | | | | | |
|-------------|--|--------------|--------------|-------------------|---------------------|------------------------------------|-----------------------------|--------------------------|---------------------|------------------|------------------|------------------|------------------------|----------------------|------------------|
| PROCURI | NG ENTITY: PHILIPPINE (| CHILI | OREN | I'S MED | ICAL CEN | | | | | | | NAME OF BI | DDER: | | |
| NAME OF | PROJECT :PHARMACEUTIC | AI SHE | PI IFS | CY 2023 | | | | | INVITATION | TO BID NO. $f I$ | B-2023-089 B | | | | |
| NAME OF | TROJECT .TTTAKWIACEOTTC. | AL SUI | LILO | C1 2025 | | | | | (| VAT EXE | MPT) | | | | |
| | PCMC REQ | QUIREN | IENT | | | | | | В | IDDER'S C | FFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM NO. ITEM DESCRIPTION QTY UNIT ABC PER UNIT NO. ITEM DESCRIPTION BRAND BRA | | | | | | | | | | | | | | ` , |
| ADDITI | ONAL REQUIREMENTS: | | | | | | | | TOT | AL = | | | | | |
| > Confor | me on the attached Terms of Refe | rence | | | | | | | | | TERMS OF DAVIME | NT (E 4:4 | - h - i ee 1 - i e 4h | !- O4b | -4-4- UNONEU |
| ➤ Drugs an | d Medicines to be delivered should have e | xpiration of | at least o | ne (1) year and l | onger or as express | ed/ required by Pharmacy | | | | | TERMS OF PAYME | N1 (For discount | s being offered, if th | ere's any. Otherwise | , state "NONE"): |
| ➤ The price | e of the bided item(s) shall be valid until De | ecember 31 | , 2023 | | | | | | | | | | | | |
| > Staggere | d delivery, staggered payment | | | | | | | | | | | | | | |
| | atities specified are estimated requirements alled for on this biddin | during the | period an | d may be decrea | sed depending upor | the actual need of PCMC. It is un | nderstood therefore that PC | CMC is not bound to orde | r / purchase all th | e items / | | | | | |
| ➤ The supp | lier should submit Materials Safety Data S | Sheet upon | delivery, it | applicable | | | | | | | NAM | ME AND SIGNAT | URE OF AUTHORIZ | ZED REPRESENTA | TIVE |
| ➤ PCMC h | as the right to reject any or all bids withou | t offering a | ny reason, | waive any requi | red formality and a | ward the contract to any bidder wh | nose proposals as evaluated | d by PCMC is the most ac | lvantageous to the | e government. | BAC & END-USER'S | S SIGNATURE: | | | |

| | | | | | | | PR | ICE SC | HEDU | L E | | | | | | |
|-------|----------------------------|---|---------------|---------------|-------------------|---------------------|-------------------------------------|----------------------------|--------------------------|----------------------|-------------------|---|--------------------------------------|---|--|---|
| ROCU | URIN | G ENTITY: PHILIPPINE C | HILD | REN | 'S MEDI | CAL CEN | <u>TER</u> | | | | | | NAME OF BI | DDER: | | |
| IAME | OF I | PROJECT : PHARMACEUTICA | L SUPI | PLIES (| CY 2023 | | | | | INVITATION | TO BID NO. $f I$ | B-2023-089 A | | | | |
| | | PCMC REQ | UIREM | IENT | | | | | | В | IDDER'S C | FFER | | | | |
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ГЕМ 1 | NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x col 12 |
| С | 1 | Hydrocortisone Sod Succ powd vl 100mg (IT,IM,IV) drypack | 1,250 | vl | 150.00 | 187,500.00 | | | | | | | | | | |
| с | 2 | Prednisone susp 10mg/5mL 60mL | 500 | bt | 91.00 | 45,500.00 | | | | | | | | | | |
| С | | | 9,250 | tab | 1.27 | 11,747.50 | | | | | | | | | | |
| С | 4 | Prednisone tab 20mg blister/foil pack | 3,650 | tab | 4.88 | 17,812.00 | | | | | | | | | | |
| | PCMC REQUIREMENT BID 1 | | | | | | | | | | | | | | | |
| DD | ITIC | ONAL REQUIREMENTS: | | | | | | | | тот | AL = | | | | | |
| • Cor | nform | ne on the attached Terms of Refere | ence | | | | | | | | | | | | | |
| Drug | s and | Medicines to be delivered should have exp | oiration of a | at least one | e (1) year and lo | nger or as expresse | d/ required by Pharmacy | | | | | TERMS OF PAYME | NT (For discounts | s being offered, if th | ere's any. Otherwise, | state "NONE") : |
| The p | price | of the bided item(s) shall be valid until Dec | ember 31, | 2023 | | | | | | | | | | | | |
| Stagg | gered | delivery, staggered payment | | | | | | | | | | | | | | |
| | | | luring the p | eriod and | may be decreas | ed depending upon | the actual need of PCMC. It is unde | erstood therefore that PCI | MC is not bound to order | / purchase all the | items / | | | | | |
| The s | suppli | er should submit Materials Safety Data She | eet upon de | elivery, if a | applicable | | | | | | | NAN | ME AND SIGNAT | URE OF AUTHORI | ZED REPRESENTAT | TIVE |
| · PCM | IC has | s the right to reject any or all bids without o | offering any | y reason, v | vaive any requir | ed formality and aw | vard the contract to any bidder who | se proposals as evaluated | by PCMC is the most adv | vantageous to the | government. | BAC & END-USER'S | SIGNATURE: | | | |
| | | | | | - | | | | | | | | | | | |

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 3 4 5 7 9 10 11 12 13 14 15 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL LOCAL LABOR, OTHER TAXES DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER FINAL NO. PRICE EXW ITEM DESCRIPTION QTY UNIT TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW MATERIAL. ITEM IF DESTINATION OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 Bleomycin Sulf powd vl 15units 107,250.00 vl1,787.50 (IM, IV, SC) Calcium Folinate vl 50mg 2 5,247 vl944,460.00 D 180.00 (IM,IV) Carboplatin soln/powd vl 280,350.00 315 vl890.00 150mg (IV) Carboplatin soln/powd vl 615 3,900.00 2,398,500.00 vl450mg (IV) Cisplatin soln 1mg/mL vl D 36,300.00 200 vl181.50 10mL (IV) Cisplatin soln 1mg/mL vl D 800 360,000.00 vl450.00 50mL (IV) Cyclophosphamide powd vl D 2,500 vl220.00 550,000.00 500mg (IV) 8 Cytarabine vl 1g, 10mL (IV inf) vl 825.00 866,250.00 Cytarabine vl 500mg, 5mL (IV, 274,480.00 D 730 vl376.00 SC infusion) 10 Cytarabine vl 100mg (IT,IV) 639,080.00 4,916 vl130.00

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 3 4 5 9 10 11 12 13 14 15 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL LOCAL LABOR, OTHER TAXES DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER **FINAL** NO. PRICE EXW ITEM DESCRIPTION QTY UNIT TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW MATERIAL. ITEM IF DESTINATION OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 Dacarbazine 200 mg Powder 100,002.00 140 vl714.30 for Injection vial 12 Dactinomycin powd vl 500mcg 388 vl 170,720.00 440.00 Dexamethasone tab 4mg 13 228,000.00 9,120 tab 25.00 blister/foil pack Doxorubicin HCl 860 172.70 148,522.00 vl powd/solution vl 10mg (IV) Doxorubicin HCl D 15 257,400.00 1,560 vl165.00 powd/solution vl 50mg (IV) Etoposide amp/vl 20mg/mL, amp/ vl D 2,021 297.00 600,237.00 5mL (IV) Filgrastim (G-CSF) vl D 17 8,868 vl1,590.00 14,100,120.00 300mcg/mL (IV,SC) 18 Fluorouracil vl 500mg IV 3,740.00 50 vl 74.80 Idarubicin HCl vl powder 5mg 70 426,300.00 D 19 vl6,090.00 (IV) 20 Ifosfamide vl 1g (IV infusion) 1,500.00 840,000.00 560 vl

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 3 4 5 9 10 11 12 13 14 15 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL LOCAL LABOR, OTHER TAXES DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER FINAL NO. UNIT PRICE EXW ITEM DESCRIPTION QTY TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW MATERIAL. ITEM IF DESTINATION OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 Ifosfamide vl 2g (IV infusion) 263,175.00 145 vl1,815.00 D 22 Imatinib 100mg tab 37,050 94.82 3,513,081.00 tab Irinotecan 40 mg/2mL(HCl) 23 760,000.00 400 vl1,900.00 concentrate, vl (IV infusion) L-Asparaginase lyoph powd vl 1,560 vl1,182.50 1,844,700.00 10,000IU (IV) Mercaptopurine tab 50mg D 133,000 26.76 3,559,080.00 25 tab blister/foil pack D 26 Mesna amp 400mg/4mL (IV) 565,950.00 3,500 amp 161.70 Methotrexate Sod (Preservative 3,675 27 Free) vl 100mg/mL, 10mL vl5,505.50 20,232,712.50 (IV,Intrathecal) Methotrexate Sod (Preservative 28 Free) vl 25mg/mL, 2mL 2,793 vl205.50 573,961.50 (IM,IV,Intrathec) Methotrexate Sod tab 2.5mg 29 525,921.70 113,590 tab 4.63 blister/foil pack Morphine 10 mg Modified 30 600 15,996.00 tab 26.66 Release Tablet

PRICE SCHEDULE PROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER NAME OF BIDDER: INVITATION TO BID NO. IB-2023-089 B NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2023 (VAT EXEMPT) PCMC REQUIREMENT BIDDER'S OFFER 2 3 4 5 9 10 11 12 13 14 15 6 COST OF UNIT PRICES SALES AND TOTAL PRICE FINAL LOCAL LABOR, OTHER TAXES DELIVERED TOTAL ITEM DESTINATION ABC PER COUNTRY UNIT RAW PAYABLE PER **FINAL** NO. UNIT PRICE EXW ITEM DESCRIPTION QTY TOTAL ABC ITEM DESCRIPTION BRAND MANUFACTURER AND UNIT PRICE UNIT OF ORIGIN PRICE EXW MATERIAL, ITEM IF DESTINATION OF OTHER (cols. 2 x 10) AND CONTRACT IS (col 13+14) x col INCIDENTAL COMPONENT AWARDED SERVICES 12 Morphine Sulf amp 10mg/mL, 10,205.00 130 78.50 amp 1mL (IM,IV) Ondansetron amp 2mg/mL, 32 11,567 450.00 5,205,150.00 D amp 4mL (IV) Ondansetron HCl tab 8mg 33 120,400.00 1,720 tab 70.00 blister/foil pack 34 Rituximab 100mg inj. 10mL vial vl9,783.74 293,512.20 35 Rituximab 500mg inj. 50mL vial 33,371.37 1,835,425.35 vl36 Sirolimus 0.5mg tab 617,500.00 4,750 tab 130.00 D 37 Sirolimus 1mg tab 500 tab 208.01 104,005.00 Vinblastine Sulf powd vl 10mg 596 596,596.00 vl1,001.00 (IV) Vincristine Sulf vl 1mg/mL, 39 633,408.00 D 1,600 vl395.88 1mL (IV) Vincristine Sulf vl 1mg/mL, 40 4,810 vl436.15 2,097,881.50 2mL (IV) TOTAL = 66,700,371.75

| | | | | | | PR | ICE SC | HEDU | L.E | | | | | | |
|-------------|--|--------------|--------------|-------------------|---------------------|------------------------------------|-----------------------------|--------------------------|---------------------|------------------|------------------|------------------|------------------------|----------------------|------------------|
| PROCURI | NG ENTITY: PHILIPPINE (| CHILI | OREN | I'S MED | ICAL CEN | | | | | | | NAME OF BI | DDER: | | |
| NAME OF | PROJECT :PHARMACEUTIC | AI SHE | PI IFS | CY 2023 | | | | | INVITATION | TO BID NO. $f I$ | B-2023-089 B | | | | |
| NAME OF | TROJECT .TTTAKWIACEOTTC. | AL SUI | LILO | C1 2025 | | | | | (| VAT EXE | MPT) | | | | |
| | PCMC REQ | QUIREN | IENT | | | | | | В | IDDER'S C | FFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM NO. ITEM DESCRIPTION QTY UNIT ABC PER UNIT NO. ITEM DESCRIPTION BRAND BRA | | | | | | | | | | | | | | ` , |
| ADDITI | ONAL REQUIREMENTS: | | | | | | | | TOT | AL = | | | | | |
| > Confor | me on the attached Terms of Refe | rence | | | | | | | | | TERMS OF DAVIME | NT (E 4:4 | - h - i ee 1 - i e 4h | !- O4b | -4-4- UNONEU |
| ➤ Drugs an | d Medicines to be delivered should have e | xpiration of | at least o | ne (1) year and l | onger or as express | ed/ required by Pharmacy | | | | | TERMS OF PAYME | N1 (For discount | s being offered, if th | ere's any. Otherwise | , state "NONE"): |
| ➤ The price | e of the bided item(s) shall be valid until De | ecember 31 | , 2023 | | | | | | | | | | | | |
| > Staggere | d delivery, staggered payment | | | | | | | | | | | | | | |
| | atities specified are estimated requirements alled for on this biddin | during the | period an | d may be decrea | sed depending upor | the actual need of PCMC. It is un | nderstood therefore that PC | CMC is not bound to orde | r / purchase all th | e items / | | | | | |
| ➤ The supp | lier should submit Materials Safety Data S | Sheet upon | delivery, it | applicable | | | | | | | NAM | ME AND SIGNAT | URE OF AUTHORIZ | ZED REPRESENTA | TIVE |
| ➤ PCMC h | as the right to reject any or all bids withou | t offering a | ny reason, | waive any requi | red formality and a | ward the contract to any bidder wh | nose proposals as evaluated | d by PCMC is the most ac | lvantageous to the | e government. | BAC & END-USER'S | S SIGNATURE: | | | |